US20030144209A1 - Amino -terminal modified parathyroid hormone (PTH) analogs - Google Patents
Amino -terminal modified parathyroid hormone (PTH) analogs Download PDFInfo
- Publication number
- US20030144209A1 US20030144209A1 US10/361,928 US36192803A US2003144209A1 US 20030144209 A1 US20030144209 A1 US 20030144209A1 US 36192803 A US36192803 A US 36192803A US 2003144209 A1 US2003144209 A1 US 2003144209A1
- Authority
- US
- United States
- Prior art keywords
- desamino
- peptide
- hpth
- ser
- pth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000445 Parathyroid hormone Proteins 0.000 title description 62
- 102000003982 Parathyroid hormone Human genes 0.000 title description 60
- 239000000199 parathyroid hormone Substances 0.000 title description 59
- 229960001319 parathyroid hormone Drugs 0.000 title description 42
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 135
- RRBCHMCWWOHRQL-UMXFMPSGSA-N parathyroid hormone (1-34)amide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CN=CN1 RRBCHMCWWOHRQL-UMXFMPSGSA-N 0.000 claims abstract description 34
- 150000001413 amino acids Chemical group 0.000 claims abstract description 32
- 239000012634 fragment Substances 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- OXZNHYPGOAWYLT-FISSOZIDSA-N ostabolin Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)OC(=O)CC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C1C=NC=N1 OXZNHYPGOAWYLT-FISSOZIDSA-N 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 146
- 238000000034 method Methods 0.000 claims description 50
- 210000000988 bone and bone Anatomy 0.000 claims description 37
- 230000014509 gene expression Effects 0.000 claims description 29
- 108091033319 polynucleotide Proteins 0.000 claims description 24
- 102000040430 polynucleotide Human genes 0.000 claims description 24
- 108020004414 DNA Proteins 0.000 claims description 23
- 239000002157 polynucleotide Substances 0.000 claims description 23
- 239000013598 vector Substances 0.000 claims description 22
- 238000001727 in vivo Methods 0.000 claims description 11
- 208000001132 Osteoporosis Diseases 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 7
- 108020004511 Recombinant DNA Proteins 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 208000006386 Bone Resorption Diseases 0.000 claims description 2
- 230000010072 bone remodeling Effects 0.000 claims description 2
- 230000024279 bone resorption Effects 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims 1
- 101710149426 Parathyroid hormone 2 receptor Proteins 0.000 abstract description 37
- 102100030869 Parathyroid hormone 2 receptor Human genes 0.000 abstract description 37
- 102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 abstract description 36
- 101710180613 Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 abstract description 34
- 238000006467 substitution reaction Methods 0.000 abstract description 13
- 239000000018 receptor agonist Substances 0.000 abstract description 5
- 229940044601 receptor agonist Drugs 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 description 63
- 102000004196 processed proteins & peptides Human genes 0.000 description 54
- 102000014384 Type C Phospholipases Human genes 0.000 description 49
- 108010079194 Type C Phospholipases Proteins 0.000 description 49
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 46
- 230000004913 activation Effects 0.000 description 43
- 102000005962 receptors Human genes 0.000 description 41
- 108020003175 receptors Proteins 0.000 description 41
- 230000000694 effects Effects 0.000 description 40
- 235000001014 amino acid Nutrition 0.000 description 32
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 30
- 102000030621 adenylate cyclase Human genes 0.000 description 28
- 108060000200 adenylate cyclase Proteins 0.000 description 28
- 125000003275 alpha amino acid group Chemical group 0.000 description 26
- 108010049264 Teriparatide Proteins 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 23
- 229920001184 polypeptide Polymers 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- 101000589873 Homo sapiens Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- 102000051132 human PTH1R Human genes 0.000 description 17
- 230000011664 signaling Effects 0.000 description 17
- 102000003923 Protein Kinase C Human genes 0.000 description 16
- 108090000315 Protein Kinase C Proteins 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 239000000556 agonist Substances 0.000 description 15
- 230000001593 cAMP accumulation Effects 0.000 description 14
- 239000011575 calcium Substances 0.000 description 14
- 239000003446 ligand Substances 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 101100085138 Homo sapiens PTH1R gene Proteins 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- ULBHWNVWSCJLCO-NHCYSSNCSA-N Arg-Val-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N ULBHWNVWSCJLCO-NHCYSSNCSA-N 0.000 description 10
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 10
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- NIOYDASGXWLHEZ-CIUDSAMLSA-N Ser-Met-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O NIOYDASGXWLHEZ-CIUDSAMLSA-N 0.000 description 10
- AIISTODACBDQLW-WDSOQIARSA-N Trp-Leu-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 AIISTODACBDQLW-WDSOQIARSA-N 0.000 description 10
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 10
- 108010062796 arginyllysine Proteins 0.000 description 10
- 210000004899 c-terminal region Anatomy 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 102000058004 human PTH Human genes 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- WIDVAWAQBRAKTI-YUMQZZPRSA-N Asn-Leu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIDVAWAQBRAKTI-YUMQZZPRSA-N 0.000 description 9
- WVYJNPCWJYBHJG-YVNDNENWSA-N Glu-Ile-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O WVYJNPCWJYBHJG-YVNDNENWSA-N 0.000 description 9
- POMXSEDNUXYPGK-IHRRRGAJSA-N Leu-Met-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N POMXSEDNUXYPGK-IHRRRGAJSA-N 0.000 description 9
- OWRUUFUVXFREBD-KKUMJFAQSA-N Lys-His-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O OWRUUFUVXFREBD-KKUMJFAQSA-N 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 8
- 101001084266 Homo sapiens Parathyroid hormone 2 receptor Proteins 0.000 description 8
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 8
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 8
- 229940095074 cyclic amp Drugs 0.000 description 8
- -1 e.g. Chemical group 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- IXFVOPOHSRKJNG-LAEOZQHASA-N Gln-Asp-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IXFVOPOHSRKJNG-LAEOZQHASA-N 0.000 description 7
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000013270 controlled release Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 201000008968 osteosarcoma Diseases 0.000 description 7
- 239000002287 radioligand Substances 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 6
- 102000006461 Parathyroid Hormone Receptors Human genes 0.000 description 6
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 description 6
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 6
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000010647 peptide synthesis reaction Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 5
- 101100031555 Rattus norvegicus Pth1r gene Proteins 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 241000187747 Streptomyces Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000013599 cloning vector Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- OMSMPWHEGLNQOD-UWVGGRQHSA-N Asn-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMSMPWHEGLNQOD-UWVGGRQHSA-N 0.000 description 4
- 101710095468 Cyclase Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 4
- 101710191547 Peptidyl-tRNA hydrolase 1 Proteins 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 239000004031 partial agonist Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- QFVODVAZJVCZIQ-INNSVFCQSA-N 51257-86-4 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)OC(=O)CC[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1N=CN=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)OC(=O)CC[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)OC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1N=CN=C1)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)C(C)C)C1=CC=CC=C1 QFVODVAZJVCZIQ-INNSVFCQSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
- SBVMXEZQJVUARN-XPUUQOCRSA-N Gly-Val-Ser Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O SBVMXEZQJVUARN-XPUUQOCRSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000037147 Hypercalcaemia Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 101710191540 Peptidyl-tRNA hydrolase 2 Proteins 0.000 description 3
- 101710202918 Peptidyl-tRNA hydrolase 2, mitochondrial Proteins 0.000 description 3
- 102100030867 Peptidyl-tRNA hydrolase 2, mitochondrial Human genes 0.000 description 3
- 101710149528 Probable peptidyl-tRNA hydrolase 2 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000008512 biological response Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000000148 hypercalcaemia Effects 0.000 description 3
- 208000030915 hypercalcemia disease Diseases 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108010040335 parathyroid hormone (3-34) Proteins 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 description 2
- 208000013038 Hypocalcemia Diseases 0.000 description 2
- 208000000038 Hypoparathyroidism Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 108700003690 bovine parathyroid hormone (1-34) Proteins 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004640 cellular pathway Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 230000000705 hypocalcaemia Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 241000203809 Actinomycetales Species 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100505076 Caenorhabditis elegans gly-2 gene Proteins 0.000 description 1
- 101100067721 Caenorhabditis elegans gly-3 gene Proteins 0.000 description 1
- 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 description 1
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102100040577 Dermatan-sulfate epimerase-like protein Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000289427 Didelphidae Species 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 description 1
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- JENKOCSDMSVWPY-SRVKXCTJSA-N His-Leu-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O JENKOCSDMSVWPY-SRVKXCTJSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000816741 Homo sapiens Dermatan-sulfate epimerase-like protein Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- KUHFPGIVBOCRMV-MNXVOIDGSA-N Ile-Gln-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)N KUHFPGIVBOCRMV-MNXVOIDGSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- APFJUBGRZGMQFF-QWRGUYRKSA-N Leu-Gly-Lys Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN APFJUBGRZGMQFF-QWRGUYRKSA-N 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- FGAMAYQCWQCUNF-DCAQKATOSA-N Met-His-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N FGAMAYQCWQCUNF-DCAQKATOSA-N 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108050006002 RNA polymerase sigma factor FliA Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical class C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 108700000288 parathyroid hormone (1-28) Proteins 0.000 description 1
- 108010057748 parathyroid hormone (2-34) Proteins 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- MJIBOYFUEIDNPI-HBNMXAOGSA-L zinc 5-[2,3-dihydroxy-5-[(2R,3R,4S,5R,6S)-4,5,6-tris[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxy]-2-[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxymethyl]oxan-3-yl]oxycarbonylphenoxy]carbonyl-3-hydroxybenzene-1,2-diolate Chemical class [Zn++].Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c([O-])c([O-])c2)c1 MJIBOYFUEIDNPI-HBNMXAOGSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to novel parathyroid hormone peptide (PTH) derivatives.
- PTH parathyroid hormone peptide
- the invention relates to PTH derivatives having one or more amino acid substitutions that confer PTH-1/PTH-2 receptor agonist or antagonist properties to the derivatives.
- PTH parathyroid hormone
- PTHrP PTH-related peptide
- PTH In renal and osteoblastic cell lines, PTH triggers several parallel intracellular signaling responses, including activation of adenylyl cyclase (AC), protein kinase A (PKA), phospholipase C (PLC) and protein kinase C (PKC) and generation of second messengers such as cyclic AMP (cAMP), inositol trisphosphate (IP 3 ), diacylglycerol and increased cytosolic free calcium (Ca i ++ ) (Abou-Samra, A. B., et al., Proc. Natl. Acad. Sci. U.S.A.
- the first of these, type A was isolated from both bone and kidney cells and shown to transduce multiple signaling responses to PTH-(1-34) or PTHrP(1-36) when heterologously expressed in cells that lack endogenous type 1 PTH/PTHrP receptors (PTHRs) (Abou-Samra, A. B., et al., Proc. Natl. Acad Sci. U.S.A. 89(7):2732-2736 (1992); Azarani, A., et al., J. Biol. Chem. 271(25): 14931-14936 (1996); Bringhurst, F.
- PTHRs type 1 PTH/PTHrP receptors
- region hPTH-(29-32) was identified specifically as a critical PKC activation domain (Jouis Subscribe, H., et al., J. Bone Miner. Res. 9(6):943-949 (1994); Whitfield, J. F., and Morley, P. Trends Pharm. Sci. 16(11):382-386 (1995)).
- hPTH-(3-34) The effects of hPTH-(3-34) on Ca i ++ are similarly controversial (Pines, M., et al., Bone 18(4):381-389 (1996); Jobert, A.-S., et al., Endocrinology 138(12):5282-5292 (1997)), while the roles of other regions of the hPTH-(1-34) molecule in signaling via the human PTHR have not been systematically addressed.
- hPTH-(1-31) shown by others to be a full AC agonist but to be incapable of activating PKC via rodent PTHRs (Jouis Subscribe, H., et al., Endocrinology 130(1):53-60 (1992)), was as potent as hPTH-(1-34) in activating both AC and PLC via human PTHRs expressed in LLC-PK1, COS-7 or HEK 293 cells (Takasu, H., and Bringhurst, F. R., Endocrinology 139(10):4293-4299 (1998)).
- the present invention is directed to amino terminal modifications of human parathyroid hormone 1-34 peptide which selectively activate the PTH-2 receptor much more effectively than does the native hPTH(1-34)NH 2 ligand but which still activate the classical, PTH-1 receptor, albeit at a reduced level.
- This unexpected finding has important implications for the design of excellent receptor selective PTH agonists in systems including in vivo where both receptors are expressed.
- the desamino peptides of the present invention are still signal selective via the PTH-1 receptor in that they possess some cAMP activity but minimal PLC activity. Accordingly, the desamino peptides described herein will be useful as bone anabolic agents for the therapeutic treatment of bone disease in vivo.
- the present invention relates to PTH(1-34) peptides and derivatives thereof.
- Compounds of the invention which include PTH(1-34) peptides, fragments thereof, derivatives thereof, pharmaceutically acceptable salts thereof, and N- or C-derivatives thereof, are hereinafter collectively referred to as “compounds of SEQ ID NO:1 and derivatives thereof.”
- the invention provides synthetic and/or recombinant biologically active peptide derivatives of PTH(1-34).
- this invention provides a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula:
- X 01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser 1 hPTH(1-31 )NH 2 or desamino Ser 1 hPTH(1-34)NH 2 .
- compositions comprising a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula:
- X 01 is desamino Ser, desamino Ala or desamino Gly; and a pharmaceutically acceptable carrier.
- this invention provides a nucleic acid molecule consisting essentially of a polynucleotide encoding a biologically active peptide which has an amino acid sequence selected from the group consisting of:
- X 01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser 1 hPTH(1-31)NH 2 or desamino Ser 1 hPTH(1-34)NH 2 .
- this invention provides a recombinant DNA molecule comprising: (1) an expression control region, said region in operable linkage with (2) a polynucleotide sequence coding for a biologically active peptide, wherein said peptide is selected from the group consisting of:
- X 01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser 1 hPTH(1-3)NH 2 or desamino Ser 1 hPTH(1-34)NH 2 .
- this invention provides a method for treating mammalian conditions characterized by decreases in bone mass, which method comprises administering to a subject in need thereof an effective bone mass-increasing amount of a biologically active peptide, wherein said peptide comprises an amino acid sequence at least 90% identical to a member selected from the group consisting essentially of:
- X 01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser 1 hPTH(1-31)NH 2 or desamino Ser 1 hPTH(1-34)NH 2 ; and a pharmaceutically acceptable carrier.
- a method for treating a medical disorder that results from altered or excessive action of the PTH-2 receptor comprising administering to a patient a therapeutically effective amount of a biologically active peptide wherein said peptide comprises an amino acid sequence at least 90% identical to a member selected from the group consisting essentially of:
- X 01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser 1 hPTH(1-31)NH 2 or desamino Ser 1 hPTH(1-34)NH 2 ; and a pharmaceutically acceptable carrier sufficient to activate the PTH-2 receptor but not the PTH-1 of said patient.
- this invention also provides a method for determining rates of bone reformation, bone resorption and/or bone remodeling comprising administering to a patient an effective amount of a labeled peptide of SEQ ID NO: 1 or a derivative thereof and determining the uptake of said peptide into the bone of said patient.
- the peptide may be labeled with a label selected from the group consisting of: radiolabel, flourescent label, bioluminescent label, or chemiluminescent label.
- An example of a suitable radiolabel is 99m Tc.
- any amino-acid substitutions at positions 1-34, and more particularly those amino acid substitutions at amino acid position 1, which do not destroy the biological activity of the PTH(1-34) peptide analog to selectively agonize the PTH-1/PTH-2 receptor are also included within the scope of the present invention.
- FIG. 1 Measurements of cyclic AMP accumulation in HKRK C53 cells. These are LLC-PK 1 porcine renal cells, which stably express approximately 150,000 recombinant hPTH-1 receptors per cell. Data are presented for two concentrations of peptide (10 ⁇ 9 M( ⁇ ) and 10 ⁇ 7 M ( ⁇ ). It can be seen that the Ala 1 - and Gly 1 -substituted hPTH(1-34)NH 2 molecules have nearly the same efficacy in this assay as does native hPTH(1-34)NH 2 , whereas their desamino counterparts have greatly reduced activity, particularly noticeable at the 1 nM concentration. The peptide hPTH(2-34) has similarly reduced activity via the PTH-1 receptor.
- FIG. 2 cAMP measurements in SaOS-2 cells are transformed human osteosarcoma cells which are known to express relatively few (10,000-20,000 per cell) human PTH-1 receptors.
- the cyclase activity of the [Gly 1 ] ( ⁇ ) and [Ala 1 ] hPTH(1-34)NH 2 ( ⁇ ) analogs again is comparable to that of the control peptide hPTH(1-34) peptide ( ⁇ ), whereas the desamino-[Ala 1 ]( ⁇ ) and -[Gly 1 ]( ⁇ ) peptides, like the hPTH(2-34) peptide, display minimal activity, even at very high concentrations (i.e., micromolar).
- FIG. 3 cAMP measurements in clonal LLC-PK 1 cells (HPR2-7).
- Clonal LLC-PK 1 cells (HPR2-7) express approximately 250,000 recombinant human PTH-2 receptors per cell.
- Desamino-[Ala 1 ]( ⁇ ) and -[Gly 1 ]( ⁇ ) peptides display enhanced efficacy in comparison with hPTH(1-34)NH 2 ( ⁇ ), hPTH(2-34) ( ⁇ ) or their [Ala 1 ]( ⁇ ) and [Gly 1 ]( ⁇ ) substituted counterparts.
- the desamino peptides displayed a substantially greater maximal cyclase activation at very high concentrations (1 micromolar).
- FIG. 4 Measurements of phospholipase C (PLC) activity in LLC-PK cells (HKRK-B7) that stably express approximately 1 million human PTH-1 receptors per cell. Desamino-[Ala 1 ] and -[Gly 1 ] compounds exert no activation of PLC via this receptor, whereas hPTH(1-34)NH 2 and [Ala 1 ]hPTH(1-34)NH 2 are full agonists. [Gly 1 ]hPTH(1-34)NH 2 and hPTH(1-34)NH 2 are only partial agonists for PLC activation via the type 1 hPTH receptor). Human PTH(2-34), like the desamino peptides, is inactive in this assay (1000 nM concentration).
- FIG. 5 Phospholipase C activating profiles of these peptides in cells (HPR2-22) that express 1.5 million recombinant human PTH-2 receptors per cell. As seen in the figure, both desamino peptides exert greater maximal activation of phospholipase C at the concentration tested (1,000 nM) than does human PTH (1-34)NH 2 . Human PTH(2-34), which has activity similar to the desamino peptides via the PTH-1 receptor, is seen to be only a partial agonist in this assay.
- FIG. 6 Radioligand binding of hPTH analogs.
- the enhanced potency of the desamino peptides for the PTH-2 receptor is associated with a 10-fold higher apparent binding affinity, relative to hPTH(1-34), to that receptor (vs the PTH-1 receptor).
- hPTH(1-34)( ⁇ ), HPTH(2-34)( ⁇ ) and the desamino peptides exhibit similar competitive displacement of 125 I-[Nle 8,21 ]rPTH(1-34) radioligand binding to HKRK B28 cells that express 280,000 recombinant PTH-1 receptors/cell, whereas the desamino compounds are 10-fold more potent in displacing this radioligand from HPR2-7 cells that express the human PTH-2 receptor.
- Cloning vector A plasmid or phage DNA or other DNA sequence which is able to replicate autonomously in a host cell, and which is characterized by one or a small number of restriction endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without loss of an essential biological function of the vector, and into which a DNA fragment may be spliced in order to bring about its replication and cloning.
- the cloning vector may further contain a marker suitable for use in the identification of cells transformed with the cloning vector. Markers, for example, provide tetracycline resistance or ampicillin resistance.
- Expression vector A vector similar to a cloning vector but which is capable of enhancing the expression of a gene which has been cloned into it, after transformation into a host.
- the cloned gene is usually placed under the control of (i. e., operably linked to) certain control sequences such as promoter sequences.
- Promoter sequences may be either constitutive or inducible.
- a recombinant host may be any prokaryotic or eukaryotic host cell which contains the desired cloned genes on an expression vector or cloning vector. This term is also meant to include those prokaryotic or eukaryotic cells that have been genetically engineered to contain the desired gene(s) in the chromosome or genome of that organism. For examples of such hosts, see Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989). Preferred recombinant hosts are eukaryotic cells transformed with the DNA construct of the invention. More specifically, mammalian cells are preferred.
- Promoter A DNA sequence generally described as the 5′ region of a gene, located proximal to the start codon. The transcription of an adjacent gene(s) is initiated at the promoter region. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent if the promoter is a constitutive promoter. Examples of promoters include the CMV promoter (InVitrogen, San Diego, Calif.), the SV40, MMTV, and hMTIIa promoters (U.S. Pat. No. 5,457,034), the HSV-1 4/5 promoter (U.S. Pat. No. 5,501,979), and the early intermediate HCMV promoter (WO92/17581). Also, tissue-specific enhancer elements may be employed. Additionally, such promoters may include tissue and cell-specific promoters of an organsim.
- Polynucleotide This term generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. “Polynucleotides” include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.
- polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
- the term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.
- Modified bases include, for example, tritylated bases and unusual bases such as inosine.
- polynucleotide embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells.
- Polynucleotide also embraces relatively short polynucleotides, often referred to as oligonucleotides.
- Polypeptide This term refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i. e., peptide isosteres. “Polypeptide” refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. “Polypeptides” include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in the research literature.
- Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. See, for instance, Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993 and Wold, F., Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in Posttranslational Covalent Modification of Proteins, B. C.
- Homologous/Nonhomologous Two nucleic acid molecules are considered to be “homologous” if their nucleotide sequences share a similarity of greater than 40%, as determined by HASH-coding algorithms (Wilber, W. J. and Lipman, D. J., Proc. Natl. Acad. Sci. 80:726-730 (1983)). Two nucleic acid molecules are considered to be “nonhomologous” if their nucleotide sequences share a similarity of less than 40%.
- Isolated A term meaning altered “by the hand of man” from the natural state. If a composition or substance occurs in nature, the isolated form has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated,” as the term is employed herein. Thus, a polypeptide or polynucleotide produced and/or contained within a recombinant host cell is considered isolated for purposes of the present invention.
- isolated polypeptide or an “isolated polynucleotide” are polypeptides or polynucleotides that have been purified, partially or substantially, from a recombinant host cell or from a native source.
- a recombinantly produced version of compounds of SEQ ID NO:1 and derivatives thereof can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988).
- Identity This term refers to a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. “Identity” per se has an art-recognized meaning and can be calculated using published techniques. (See, e.g.: Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H.
- identity is well known to skilled artisans (Carillo, H. & Lipton, D., SIAM J Applied Math 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J.
- Fragment A “fragment” of a molecule such as a compound of SEQ ID NO: 1 or derivative thereof is meant to refer to any polypeptide subset of these molecules.
- Derivatives is intended to include “variants,” the “derivatives,” or “chemical derivatives” of the molecule.
- a “variant” of a molecule such as a compound of SEQ ID NO: 1 or derivative thereof is meant to refer to a molecule substantially similar to either the entire molecule, or a fragment thereof.
- An “analog” of a molecule such as a compound of SEQ ID NO: 1 or derivative thereof is meant to refer to a non-natural molecule substantially similar to either the SEQ ID NO: 1 molecules or fragments thereof.
- a molecule is said to be “substantially similar” to another molecule if the sequence of amino acids in both molecules is substantially the same, and if both molecules possess a similar biological activity. Thus, provided that two molecules possess a similar activity, they are considered variants, derivatives, or analogs as that term is used herein even if one of the molecules contains additional amino acid residues not found in the other, or if the sequence of amino acid residues is not identical.
- a molecule is said to be a “chemical derivative” of another molecule when it contains additional chemical moieties not normally a part of the molecule. Such moieties may improve the molecule's solubility, absorption, biological half-life, etc. The moieties may alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, etc. Examples of moieties capable of mediating such effects are disclosed in Remington's Pharmaceutical Sciences (1980) and will be apparent to those of ordinary skill in the art.
- Biological Activity of the Protein refers to the metabolic or physiologic function of compounds of SEQ ID NO: 1 or derivatives thereof including similar activities or improved activities or those activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said compounds of SEQ ID NO: 1 or derivatives thereof.
- Gene Therapy A means of therapy directed to altering the normal pattern of gene expression of an organism. Generally, a recombinant polynucleotide is introduced into cells or tissues of the organism to effect a change in gene expression.
- Host Animal Transgenic animals, all of whose germ and somatic cells contain the DNA construct of the invention. Such transgenic animals are in general vertebrates. Preferred host animals are mammals such as non-human primates, mice, sheep, pigs, cattle, goats, guinea pigs, rodents, e.g. rats, and the like. The term Host Animal also includes animals in all stages of development, including embryonic and fetal stages.
- the significance of this invention relates to the existence of two cloned species of parathyroid hormone receptors, PTH-1 and PTH-2. These two receptors share significant (greater than 50%) sequence homology and clearly are members of a common receptor family. They appear to be expressed in very different tissues, however. Specifically, the PTH-2 receptor is expressed in certain regions of the brain, lung, endothelium and pancreas, among others, whereas the type 1 receptor is more ubiquitously expressed, especially in kidney and bone. Until now, it has been known only that the PTH-2 receptor was selective for PTH, in that native PTH-related peptide (PTHrP) neither binds to nor activates this receptor. The PTH-2 receptor has been expressed at high levels in homologous cell systems such as HEK kidney cells and shown to signal both adenylyl cyclase and cytosolic free calcium transients.
- the present invention relates to hPTH(1-34) peptides and derivatives thereof.
- Compounds of the invention which include hPTH(1-34) peptides, fragments thereof, derivatives thereof, pharmaceutically acceptable salts thereof, and N- or C-derivatives thereof, are hereinafter collectively referred to as “compounds of SEQ ID NO:1 and derivatives thereof.”
- the invention provides synthetic and/or recombinant biologically active peptide derivatives of hPTH(1-34).
- this invention provides a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula:
- X 01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser 1 hPTH(1-31)NH 2 or desamino Ser 1 hPTH(1-34)NH 2 (SEQ ID NO:8).
- the present invention thus provides a novel hPTH (1-34) derivative that is a potent selective PTH-2 receptor agonist.
- the hPTH (1-34) derivative is altered at residue 1.
- the invention includes an hPTH (1-34) derivative having an amino acid substitution of desamino alanine or desamino glycine for serine at position 1 of hPTH (1-34).
- any other amino-acid substitutions of a nature which do not destroy the ability of the HPTH (1-34) derivative to selectively agonize the PTH-1/PTH-2 receptor (as determined by assays known to the skilled artisan and discussed below), are included in the scope of the present invention.
- compounds of SEQ ID NO: 1 or derivatives thereof of the present invention are amenable to production by the technique of solution- or solid-phase peptide synthesis.
- the solid phase peptide synthesis technique in particular, has been successfully applied in the production of human PTH and can be used for the production of compounds of SEQ ID NO: 1 or derivatives thereof of the present invention (for guidance, see Kimura et al., supra, and see Fairwell et al., Biochem. 22:2691 (1983)).
- Success with producing human PTH on a relatively large scale has been reported by Goud et al., in J. Bone Min. Res. 6(8):781 (1991), incorporated herein by reference.
- the synthetic peptide synthesis approach generally entails the use of automated synthesizers and appropriate resin as solid phase, to which is attached the C-terminal amino acid of the desired compounds of SEQ ID NO: 1 or derivatives thereof. Extension of the peptide in the N-terminal direction is then achieved by successively coupling a suitably protected form of the next desired amino acid, using either FMOC- or BOC-based chemical protocols typically, until synthesis is complete. Protecting groups are then cleaved from the peptide, usually simultaneously with cleavage of peptide from the resin, and the peptide is then isolated and purified using conventional techniques, such as by reversed phase HPLC using acetonitrile as solvent and tri-fluoroacetic acid as ion-pairing agent.
- substituents may be attached to the free amine of the N-terminal amino acid of compounds of SEQ ID NO: 1 or derivatives thereof by standard methods known in the art.
- alkyl groups e.g., C 1-12 alkyl
- Hydroxyalkyl groups e.g. C 1-12 hydroxyalkyl
- Acyl groups e.g., COE 1
- Also contemplated within the scope of this invention are those compounds of SEQ ID NO:1 and derivatives thereof that alter secondary or tertiary structure, or stability of compounds of SEQ ID NO: 1 or derivatives thereof which still retain biological activity.
- Such derivatives might be achieved through lactam cyclization, disulfide bonds, or other means known to a person of ordinary skill in the art.
- preferred embodiments of the invention are those compounds which may serve as selective agonists of the PTH-1/PTH-2 receptor
- preferred embodiments are those compounds where X 01 is desamino Gly.
- the amino acid sequence of this preferred embodiment is thus desaminoGlyValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO: 2) or derivatives thereof. [[desaminoGly 1 ]hPTH(1-34)].
- Another set of the preferred embodiments are those compounds having a one amino acid deletion at the carboxy terminus of SEQ ID NO: 2 where X 01 is desamino Gly.
- the amino acid sequence of this preferred embodiment is thus desaminoGlyValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsn (SEQ ID NO: 3) or derivatives thereof. [[desaminoGly 1 ]hPTH(1-33)].
- Another set of the preferred embodiments are those compounds having a seven amino acid deletion at the carboxy terminus of SEQ ID NO: 2 where X 01 is desamino Gly.
- the amino acid sequence of this preferred embodiment is thus desaminoGlyValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLys (SEQ ID NO: 4) or derivatives thereof. [[desaminoGly 1 ]hPTH(1-27)].
- Another set of the preferred embodiments are those compounds where X 01 is desamino Ala.
- the amino acid sequence of this preferred embodiment is thus desaminoAlaValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO: 5) or derivatives thereof. [[desaminoAla 1 ]hPTH(1-34)].
- Another set of the preferred embodiments are those compounds having a one amino acid deletion at the carboxy terminus of SEQ ID NO: 5 where X 01 is desamino Ala.
- the amino acid sequence of this preferred embodiment is thus desaminoAlaValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsn (SEQ ID NO: 6) or derivatives thereof. [[desaminoAla 1 ]hPTH(1-33)].
- Another set of the preferred embodiments are those compounds having a seven amino acid deletion at the carboxy terminus of SEQ ID NO: 5 where X 01 is desamino Ala.
- the amino acid sequence of this preferred embodiment is thus desaminoAlaValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLys (SEQ ID NO: 7) or derivatives thereof. [[desaminoAla 1 ]hPTH(1-27)].
- Another set of the preferred embodiments are those compounds having a one amino acid deletion at the carboxy terminus of SEQ ID NO: 8 where X 01 is desamino Ser.
- the amino acid sequence of this preferred embodiment is thus desamino SerValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsn (SEQ ID NO: 9) or derivatives thereof. [[desaminoSer 1 ]hPTH(1-33)].
- Another set of the preferred embodiments are those compounds having a seven amino acid deletion at the carboxy terminus of SEQ ID NO: 8 where X 01 is desamino Ser.
- the amino acid sequence of this preferred embodiment is thus desaminoSerValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLys (SEQ ID NO: 10) or derivatives thereof. [[desaminoSer 1 ]hPTH(1-27)].
- the present invention also relates to vectors that comprise a polynucleotide of the present invention, and host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.
- Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of present invention.
- host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention.
- Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) such as calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.
- Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells; fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.
- chromosomal, episomal and virus-derived systems e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses, and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.
- viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses, and retroviruses
- vectors derived from combinations thereof such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemid
- the expression systems may contain control regions that regulate as well as engender expression.
- any system or vector suitable to maintain, propagate or express polynucleotides to produce a polypeptide in a host may be used.
- the appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., Molecular Cloning: A Laboratory Manual (supra).
- RNA vectors may also be utilized for the expression of the nucleic acids encoding compounds of SEQ ID NO: 1 or derivatives thereof disclosed in this invention. These vectors are based on positive or negative strand RNA viruses that naturally replicate in a wide variety of eukaryotic cells (Bredenbeek, P. J. & Rice, C. M., Virology 3: 297-310, 1992). Unlike retroviruses, these viruses lack an intermediate DNA life-cycle phase, existing entirely in RNA form.
- alpha viruses are used as expression vectors for foreign proteins because they can be utilized in a broad range of host cells and provide a high level of expression; examples of viruses of this type include the Sindbis virus and Semliki Forest virus (Schlesinger, S., TIBTECH 11:18-22, 1993; Frolov, I., et al., Proc. Natl. Acad. Sci. (USA) 93: 11371-11377, 1996).
- the investigator may conveniently maintain the recombinant molecule in DNA form (pSinrep5 plasmid) in the laboratory, but propagation in RNA form is feasible as well.
- the vector containing the gene of interest exists completely in RNA form and may be continuously propagated in that state if desired.
- secretion signals may be incorporated into the desired polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.
- control regions are a linkage in which the control or regulatory DNA sequences and the DNA sequence sought to be expressed are connected in such a way as to permit gene expression.
- the precise nature of the “control regions” needed for gene expression may vary from organism to organism, but shall in general include a promoter region which, in prokaryotic cells, contains both the promoter (which directs the initiation of RNA transcription) as well as DNA sequences which, when transcribed into RNA, will signal the initiation of protein synthesis. Regulatory regions in eukaryotic cells will in general include a promoter region sufficient to direct the initiation of RNA synthesis.
- Two DNA sequences are said to be operably linked if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frameshift mutation, (2) interfere with the ability of the promoter region sequence to direct the transcription of the fusion protein-encoding sequence or (3) interfere with the ability of the fusion protein-encoding sequence to be transcribed by the promoter region sequence.
- a promoter region would be operably linked to a DNA sequence if the promoter were capable of transcribing that DNA sequence.
- the joining of various DNA fragments, to produce the expression vectors of this invention is performed in accordance with conventional techniques, employing blunt-ended or staggered-ended termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkali and phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases.
- the genetic construct encodes an inducible promoter which is operably linked to the 5′ gene sequence of the fusion protein to allow efficient expression of the fusion protein.
- SEQ ID NO: 1 or derivatives thereof in a prokaryotic cell (such as, for example, E. coli, B. subtilis, Pseudomonas, Streptomyces, etc.), it is necessary to operably link the SEQ ID NO: 1-encoding DNA sequence to a functional prokaryotic promoter.
- a prokaryotic promoter such as, for example, E. coli, B. subtilis, Pseudomonas, Streptomyces, etc.
- Such promoters may be either constitutive or, more preferably, regulatable (i.e., inducible or derepressible).
- constitutive promoters include the int promoter of bacteriophage ⁇ , the bla promoter of the ⁇ -lactamase gene of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene of pBR325, etc.
- inducible prokaryotic promoters include the major right and left promoters of bacteriophage ⁇ , (PL and PR), the trp, recA. lacZ. lac. and gal promoters of E. coli, the ⁇ -amylase (Ulmanen, I. et al., J. Bacteriol. 162:176-182 (1985)), and the ⁇ -28-specific promoters of B.
- subtilis (Gilman, M. Z. et al., Gene 32:11-20 (1984)), the promoters of the bacteriophages of Bacillius (Gryczan, T. J., In: The Molecular Biology of the Bacilli, Academic Press, Inc., NY (1982)), and Streptomyces promoters (Ward, J. M. et al., Mol. Gen. Genet. 203:468-478 (1986)).
- Prokaryotic promoters are reviewed by Glick, B. R., J. Ind. Microbiol. 1:277-282 (1987); Cenatiempo, Y., Biochimie 68:505-516 (1986)); and Gottesman, S., Ann. Rev. Genet. 18:415-442(1984)).
- a promoter capable of directing transcription in such a eukaryotic host include the promoter of the mouse metallothionein I gene (Hamer, D. et al., J. Mol. Appl. Gen.
- the introduced DNA sequence will be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host.
- a plasmid or viral vector capable of autonomous replication in the recipient host.
- Any of a wide variety of vectors may employed for this purpose. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to “shuttle” the vector between host cells of different species.
- Preferred prokaryotic vectors include, without limitation, plasmids such as those capable of replication in E. coli (such as, for example, pBR322, ColEl , pSC101, pACYC 184, ⁇ VX. Such plasmids are, for example, disclosed by Maniatis, T., et al., In: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1982)).
- Preferred plasmid expression vectors include the pGFP-1 plasmid described in Gardella et al., J. Biol. Chem.
- Bacillus plasmids include pC194, pC221, pT127, etc. Such plasmids are disclosed by Gryczan, T. In: The Molecular Biology of the Bacilli, Academic Press, NY pp. 307-329 (1982).
- Suitable Streptomyces plasmids include pIJIOI (Kendall, K. J. et al., J. Bacteriol.
- Preferred eukaryotic expression vectors include, without limitation, BPV, vaccinia, 2-micron circle, etc.
- Such expression vectors are well known in the art (Botstein, D., et al., Miami Wntr. Symp. 19:265-274 (1982); Broach, J. R., In: The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. pp. 445-470 (1981); Broach, J. R., Cell 28:203-204 (1982); Bollon, D. P., et al., J. Clin. Hematol. Oncol. 10:39-48 (1980); Maniatis, T., In: Cell Biology: A Comprehensive Treatise, Vol. 3, Gene Expression, Academic Press, NY, pp. 563-608 (1980)).
- cultures of cells derived from multicellular organisms may also be used as hosts.
- any such cell culture is workable, whether from vertebrate or invertebrate cellular sources.
- Interest has been greater with cells from vertebrate sources.
- useful vertebrate host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, WI38, BHK, COS-7, and MDCK cell lines.
- Expression vectors for such cells ordinarily include (if necessary) an origin of replication, a promoter located in front of or upstream to the gene to be expressed, along with any necessary ribosome binding sites, RNA splice sites, polyadenylation site, and transcriptional terminator sequences.
- control functions on the expression vectors are often provided by viral material.
- viral material for example, commonly used promoters are derived from polyoma, Adenovirus 2, Simian Virus 40 (SV40) and cytomegalovirus.
- SV40 Simian Virus 40
- cytomegalovirus The early and late promoters of SV40 virus are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication (Fiers et al., Nature 273:113 (1978)).
- An origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g. Polyoma, Adeno, VSV, BPV) source or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.
- an exogenous origin such as may be derived from SV40 or other viral (e.g. Polyoma, Adeno, VSV, BPV) source or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.
- transfection is carried out by the calcium phosphate precipitation method as described by Graham and Van der Erb, Virology 52:546 (1978).
- other methods for introducing DNA into cells such as by nuclear injection or by protoplast fusion may also be used.
- the direct naked plasmid or viral DNA injection method with or without transfection-facilitating agents such as, without limitation, liposomes, provides an alternative approach to the current methods of in vivo or in vitro transfection of mammalian cells.
- the preferred method of transfection is calcium treatment, using calcium chloride as described in Cohen et al., Proc. Natl. Acad. Sci. USA 69:2110 (1972).
- compounds of SEQ ID NO: 1 or derivatives thereof of this invention, or salts thereof are administered in amounts between about 0.01 and 1 ⁇ g/kg body weight per day, preferably from about 0.07 to about 0.2 ⁇ g/kg body weight per day.
- the daily dose of biologically active compounds of SEQ ID NO: 1 or derivatives thereof is from about 0.5 to about 50 ⁇ gs, preferably from about 3.5 to about 10 ⁇ gs.
- This dosage may be delivered in a conventional pharmaceutical composition by a single administration, by multiple applications, or via controlled release, as needed to achieve the most effective results, preferably one or more times daily by injection. Most preferably, this dosage may be delivered in a conventional pharmaceutical composition by nasal insufflation.
- the selection of the exact dose and composition and the most appropriate delivery regimen will be influenced by, inter alia, the pharmacological properties of the selected compounds of SEQ ID NO: 1 or derivatives thereof, the nature and severity of the condition being treated, and the physical condition and mental acuity of the recipient.
- Representative preferred delivery regimens include, without limitation, oral, parenteral (including subcutaneous, transcutaneous, intramuscular and intravenous), rectal, buccal (including sublingual), transdermal, and intranasal insufflation.
- salts retain the desired biological activity of the compounds of SEQ ID NO: 1 or derivatives thereof without toxic side effects.
- examples of such salts are (a) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acids, naphthalene disulfonic acids, polygalacturonic acid and the like; (b) base addition salts formed with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, and
- compositions comprising as an active ingredient compounds of SEQ ID NO: 1 or derivatives thereof of the present invention, or pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable, non-toxic carrier.
- compositions may be prepared for parenteral (subcutaneous, transcutaneous, intramuscular or intravenous) administration, particularly in the form of liquid solutions or suspensions; for oral or buccal administration, particularly in the form of tablets or capsules; for rectal, transdermal administration; and for intranasal administration, particularly in the form of powders, nasal drops or aerosols.
- compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example as described in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., (1985), incorporated herein by reference.
- Formulations for parenteral administration may contain as excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like.
- the formulation can be enhanced by the addition of bile salts or acylcarnitines.
- Formulations for nasal administration may be solid and may contain excipients, for example, lactose or dextran, or may be aqueous or oily solutions for use in the form of nasal drops or metered spray.
- excipients include sugars, calcium stearate, magnesium stearate, pregelatinated starch, and the like.
- the absorption across the nasal mucous membrane may be enhanced by surfactant acids, such as for example, glycocholic acid, cholic acid, taurocholic acid, ethocholic acid, deoxycholic acid, chenodeoxycholic acid, dehydrocholic acid, glycodeoxycholic acid, cyclodextrins and the like in an amount in the range between about 0.2 and 15 weight percent, preferably between about 0.5 and 4 weight percent, most preferably about 2 weight percent.
- surfactant acids such as for example, glycocholic acid, cholic acid, taurocholic acid, ethocholic acid, deoxycholic acid, chenodeoxycholic acid, dehydrocholic acid, glycodeoxycholic acid, cyclodextrins and the like in an amount in the range between about 0.2 and 15 weight percent, preferably between about 0.5 and 4 weight percent, most preferably about 2 weight percent.
- Delivery of the compounds of the present invention to the subject over prolonged periods of time, for example, for periods of one week to one year, may be accomplished by a single administration of a controlled release system containing sufficient active ingredient for the desired release period.
- a controlled release system containing sufficient active ingredient for the desired release period.
- Various controlled release systems such as monolithic or reservoir-type microcapsules, depot implants, osmotic pumps, vesicles, micelles, liposomes, transdermal patches, iontophoretic devices and alternative injectable dosage forms may be utilized for this purpose. Localization at the site to which delivery of the active ingredient is desired is an additional feature of some controlled release devices, which may prove beneficial in the treatment of certain disorders.
- One form of controlled release formulation contains the polypeptide or its salt dispersed or encapsulated in a slowly degrading, non-toxic, non-antigenic polymer such as copoly(lactic/glycolic) acid, as described in the pioneering work of Kent, Lewis, Sanders, and Tice, U.S. Pat. No. 4,675,189, incorporated by reference herein.
- the compounds or, preferably, their relatively insoluble salts may also be formulated in cholesterol or other lipid matrix pellets, or silastomer matrix implants. Additional slow release, depot implant or injectable formulations will be apparent to the skilled artisan. See, for example, Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson ed., Marcel Dekker, Inc., New York, 1978, and R. W. Baker, Controlled Release of Biologically Active Agents, John Wiley & Sons, New York, 1987, incorporated by reference herein.
- the compounds of SEQ ID NO:1 and derivatives thereof may be administered in combination with other agents useful in treating a given clinical condition.
- the compounds of SEQ ID NO:1 and derivatives thereof may be administered in conjunction with a dietary calcium supplement or with a vitamin D analog (see U.S. Pat. No. 4,698,328).
- the compounds of SEQ ID NO:1 and derivatives thereof may be administered, preferably using a cyclic therapeutic regimen, in combination with bisphosphonates, as described for example in U.S. Pat. No. 4,761,406, or in combination with one or more bone therapeutic agents such as, without limitation, calcitonin and estrogen.
- Compounds of SEQ ID NO: 1 or derivatives thereof of this invention are useful for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass.
- the compounds of this invention are indicated for the prophylaxis and therapeutic treatment of osteoporosis and osteopenia in humans.
- the compounds of this invention are indicated for the prophylaxis and therapeutic treatment of other bone diseases.
- the compounds of this invention are indicated for the prophylaxis and therapeutic treatment of hypoparathyroidism.
- the compounds of this invention are indicated for use as agonists for fracture repair and as antagonists for hypercalcemia.
- hypercalcemia and hypocalcemia are related to the interaction between PTH and PTHrP and the PTH-1 and PTH-2 receptors.
- Hypercalcemia is a condition in which there is an abnormal elevation in serum calcium level; it is often associated with other diseases, including hyperparathyroidism, osteoporosis, carcinomas of the breast, lung and prostate, epidermoid cancers of the head and neck and of the esophagus, multiple myeloma, and hypernephroma.
- Hypocalcemia a condition in which the serum calcium level is abnormally low, may result from a deficiency of effective PTH, e.g., following thyroid surgery.
- Nucleic acids of the invention which encode compounds of SEQ ID NO: 1 or derivatives thereof may also be linked to a selected tissue-specific promoter and/or enhancer and the resultant hybrid gene introduced, by standard methods (e.g., as described by Leder et al., U.S. Pat. No. 4,736,866, herein incorporated by reference), into an animal embryo at an early developmental stage (e.g. the fertilized oocyte stage), to produce a transgenic animal which expresses elevated levels of compounds of SEQ ID NO: 1 or derivatives thereof in selected tissues (e.g., the osteocalcin promoter for bone).
- Such promoters are used to direct tissue-specific expression of compounds of SEQ ID NO: 1 or derivatives thereof in the transgenic animal.
- any other amino-acid substitutions of a nature which do not destroy the ability of the PTH analog to agonize the PTH-1/PTH-2 receptor (as determined by assays known to the skilled artisan and discussed below), are included in the scope of the present invention.
- agonist is intended a ligand capable of enhancing or potentiating a cellular response mediated by the PTH-1/PTH-2 receptor. Whether any candidate “agonist” of the present invention can enhance or inhibit such a cellular response can be determined using art-known protein ligand/receptor cellular response or binding assays, including those described elsewhere in this application.
- a method for treating osteoporosis comprising administering to a patient a therapeutically effective amount of a compound of SEQ ID NO: 1 or a derivative thereof, sufficient to selectively activate the PTH-1/PTH-2 receptor of said patient.
- the appropriate compound of SEQ ID NO: 1 or a derivative thereof is used in the manufacture of a medicament, generally by being formulated in an appropriate carrier or excipient such as, e.g., physiological saline, and preferably administered intravenously, intramuscularly, subcutaneously, orally, or intranasally, at a dosage that provides selective activation of the PTH-1/PTH-2 receptor after binding of a compound of SEQ ID NO: 1 or a derivative thereof .
- Typical dosage would be 1 ng to 10 mg of the peptide per kg body weight per day.
- Such dosages and administration may be used for administration of a PTH agonist, e.g., for treatment of conditions such as osteoporosis, other metabolic bone disorders, and hypoparathyroidism and related disorders.
- the compound of SEQ ID NO: 1 or a derivative thereof used in the method has an amino acid substitution of desamino alanine for serine at amino acid position 1 of compound of SEQ ID NO: 1.
- the PTH derivative is [desamino Ala 1 ]PTH(1-34)(SEQ ID NO: 5).
- the compound of SEQ ID NO: 1 or a derivative thereof used in the method has an amino acid substitution of desamino glycine for serine at amino acid position 1 of compound of SEQ ID NO: 1.
- the PTH derivative is [desaminoGly 1 ] PTH(1-34). (SEQ ID NO: 2)
- a crucial step in the expression of hormonal action is the interaction of hormones with receptors on the plasma membrane surface of target cells.
- the formation of hormone-receptor complexes allows the transduction of extracellular signals into the cell to elicit a variety of biological responses.
- Polypeptides of the invention may be screened for their agonistic properties using the cAMP accumulation assay.
- Cells expressing PTH-2 receptor on the cell surface are incubated with native PTH(1-84) for 5-60 minutes at 37° C., in the presence of2 mM IBMX (3-isobutyl-1-methyl-xanthine, Sigma, St. Louis, Mo.). Cyclic AMP accumulation is measured by specific radio-immunoassay, as described above.
- a compound of SEQ ID NO: 1 or a derivative thereof that competes with native PTH(1-84) for binding to the PTH-2 receptor, and which stimulates cAMP accumulation in the presence or absence of native PTH(1-84) is a competitive agonist.
- a compound of SEQ ID NO: 1 or a derivative thereof that does not compete with native PTH(1-84) for binding to the PTH-2 receptor but which is still capable of stimulating cAMP accumulation in the presence or absence of native PTH(1-84), or which stimulates a higher cAMP accumulation than that observed by a compound of SEQ ID NO: 1 or a derivative thereof alone, would be considered a non-competitive agonist.
- HKRK C53 subclones of LLC-PKI porcine renal epithelial cells which stably express human PTH-1 receptors (150,000 receptors/cell).
- SaOS-2 cells are transformed human osteosarcoma cells which express relatively few (10,000-20,000 per cell) human PTH-1 receptors.
- HPR2-7 cells are subclones of LLC-PK 1 which express approximately 250,000 recombinant human PTH-2 receptors per cell.
- HKRK-B7 cells are subclones of LLC-PK which stably express approximately 1 million hPTH-1 receptors per cell.
- HPR2-22 cells are subclones of LLC-PK1 which express 1.5 million recombinant hPTH-2 receptors per cell.
- HPR2-27 and HPR2-22 cell lines were created in the same fashion as the HKRK cells but employing instead type 2 PTH receptor cDNA using the transfection technique of (Bringhurst, F. R., el al., Endocrinology 132(5):2090-2098 (1993); Guo, J., et al., Endocrinology 136(9):3884-3891 (1995)).
- Intracellular cAMP accumulation was measured in extracts of cells that were exposed to human PTH peptides in the presence of isobutylmethyxanthine (IBMX, 1 mM) at 37° C. for 15 min. After terminating the reactions by aspiration and freezing in liquid nitrogen, cell monolayers were extracted with 50 mM HCl and cAMP was measured using a radioimmunoassay kit (Dupont-New England Nuclear, Boston, Mass.).
- IBMX isobutylmethyxanthine
- PLC was activated by PTH agonists in the presence of 30 mM LiCl at 37° C; for 30 min after 16 hr of labeling with [ 3 H]myo-inositol (3 uCi/ml) in serum-free medium containing 0.1% bovine serum albumin. The reactions were stopped by rapid aspiration and addition of cold 5% TCA. Water-soluble radiolabeled inositol trisphosphate (IP 3 ) was isolated after ether extraction by ion-exchange chromatography (Guo, J., et al., Endocrinology 136(9):3884-3891 (1995)).
- Radioligand competition binding assays were performed at 2-8° C. for 6 hr using 125 I-[Nle 8,21 ]rat PTH-(1-34)(100,000 cpm/well) in the presence or absence of non-radioactive hPTH-(1-34) analogs. Cell layers were washed three times before solubilization for determination of cell-associated radioactivity.
- the average levels basally and in the presence of maximal concentrations of hPTH-(1-34) observed in HKRK C53 cells for the assays reported here were 12 ⁇ 4 and 207 ⁇ 37 pmoles/well/15 min for cAMP accumulation, 898 ⁇ 142 and 1908 ⁇ 251 cpm/well for 1P 3 formation and 25520 ⁇ 1909 and 956 ⁇ 135 cpm/well for binding, respectively.
- the average levels basally and in the presence of maximal concentrations of hPTH-(1-34) observed in HKRK B28 cells for the assays reported here were 1.6 ⁇ 0.5 and 337 ⁇ 55 pmoles/well/15 min for cAMP accumulation, and 1497 ⁇ 121 and 16,137 ⁇ 919 cpm/well for binding, respectively.
- the average levels basally and in the presence of maximal concentrations of hPTH-(1-34) observed in HPR2-7 cells for the assays reported here were 2.5 ⁇ 1.0 and 133 ⁇ 14 pmoles/well/15 min for cAMP accumulation, and 1156 ⁇ 243 and 4541 ⁇ 386 cpm/well for binding, respectively.
- the average levels basally and in the presence of maximal concentrations of hPTH-(1-34) observed in HPR2-22 cells for the assays reported here were 5.2 ⁇ 0.5 and 286 ⁇ 8 pmoles/well/15 min for cAMP accumulation, and 335 ⁇ 68 cpm/well (basal) for IP 3 formation, respectively.
- FIG. 1 shows measurements of cyclic AMP accumulation in HKRK C53 cells.
- LLC-PK porcine renal cells, which stably express approximately 150,000 recombinant hPTH-1 receptors per cell.
- Data are presented for two concentrations of peptide (10 ⁇ 9 M and 10 ⁇ 7 M). It can be seen that the Ala 1 - and Gly 1 -substituted hPTH(1-34)NH 2 molecules have nearly the same efficacy in this assay as native hPTH(1-34)NH 2 , whereas their desamino counterparts have greatly reduced activity, particularly noticeable at the 1 nM concentration.
- the peptide hPTH(2-34) has similarly reduced activity via the PTH-1 receptor.
- FIG. 2 shows cAMP measurements in SaOS-2 cells. These are transformed human osteosarcoma cells which are known to express relatively few (10,000-20,000 per cell) human PTH-1 receptors.
- the cyclase activity of the [Gly 1 ] and [Ala 1 ] hPTH(1-34)NH 2 analogs again is comparable to that of the control peptide hPTH(1-34)NH 2 , whereas the desamino anologs, like hPTH(2-34), are very weak agonists at the highest concentration tested (1 uM).
- FIG. 3 demonstrates the cAMP responsiveness to the same peptides when they are added to other clonal LLC-PK 1 cells (HPR2-7) that express approximately 250,000 recombinant human PTH-2 receptors per cell. It is evident from FIG. 3 that the desamino-[Ala 1 ] and -[Gly 1 ] peptides display enhanced efficacy in comparison with hPTH(1-34)NH 2 , hPTH(2-34) or their [Ala 1 ] and [Gly 1 ] substituted counterparts. In addition, the desamino peptides show a substantially greater maximal cyclase activation at very high concentrations (1 micromolar).
- hPTH-(2-34) was studied in the various cell lines. As shown in FIGS. 4 and 5, hPTH-(2-34) did not elicit PLC activity in HKRK B7 cells, even though its activation of AC was comparable in magnitude and sensitivity to that of hPTH-(1-34). In addition, as shown in FIG. 6, PTH(2-34) also binds as well to the hPTH receptor as does PTH(1-34). Similar results were obtained using COS-7 cells expressing abundant human PTHRs (data not shown).
- hPTH-(2-34) The inability of hPTH-(2-34) to activate PLC via the human PTH-1 receptor was confirmed in a fully homologous system by using HEK-293 human embryonic kidney cells that were transiently transfected with human PTHR cDNA (data not shown).
- FIG. 5 Shown in FIG. 5, in contrast, are phospholipase C activating profiles of these peptides in HPR 2-22 cells that express 1.5 million recombinant hPTH-2 receptors per cell.
- both the desamino-[Ala 1 ] and -[Gly 1 ] hPTH(1-34) peptides exert greater maximal activation of phospholipase C at the concentration tested (1,000 nM) than does human PTH(1-34)NH 2 .
- Human PTH(2-34) which has activity similar to the desamino peptides via the PTH-1 receptor, is seen to be only a partial agonist in this assay.
- the enhanced potency of the desamino peptides for the PTH-2 receptor is associated with a 10-fold higher apparent binding affinity, relative to hPTH(1-34), to that receptor (vs the PTH-1 receptor).
- hPTH(1-34), HPTH(2-34) and the desamino peptides exhibit similar competitive displacement of 125 I-[Nle 8,21 ]rPTH(1-34) radioligand bind to HKRK B28 cells that express 280,000 recombinant human PTH-1 receptors/cell, whereas the desamino compounds are 10-fold more potent in displacing this radioligand from HPR2-7 cells that express the human PTH-2 receptor.
- the HKRK B7 cells were also selected for these studies to optimize analysis of the structural basis of PLC signaling via human PTHRs, which requires a high level of receptor expression (Guo, J., et al., Endocrinology 136(9):3884-3891 (1995); Pines, M., et al., Endocrinology 135(4):1713-1716 (1994)).
- N-truncated peptides were tested with other LLC-PKI subclones that expressed fewer human PTHRs (i.e. 100,000-300,000 per cell), their AC responses were indeed reduced by as much as 10-fold, relative to hPTH-(1-34) (data not shown).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
PTH derivatives having one or more amino acid substitutions that confer PTH-1/PTH-2 receptor agonist properties comprising a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula:
(a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAs nSerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1);
(b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
(c) pharmaceutically acceptable salts thereof; or
(d) N- or C-derivatives thereof;
wherein:
X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2.
Description
- This application claims the benefit of the filing date of provisional application No. 60/110,152 filed on Nov. 25, 1998, which is herein incorporated by reference.
- [0002] Part of the work performed during development of this invention utilized U.S. Government funds. The U.S. Government has certain rights in this invention.
- [0003] This work was supported by National Institutes of Health Grant DK 1 1794.
- 1. Field of the Invention
- The present invention relates to novel parathyroid hormone peptide (PTH) derivatives. In particular, the invention relates to PTH derivatives having one or more amino acid substitutions that confer PTH-1/PTH-2 receptor agonist or antagonist properties to the derivatives.
- 2. Description of Related Art
- Full understanding of the complex biological roles of parathyroid hormone (PTH) and efforts to utilize its therapeutic potential require dissection of the multiple signaling patterns and cellular pathways of action of the hormone. PTH binds and activates specific receptors in renal and osseous target cells that also recognize PTH-related peptide (PTHrP) (Kronenberg, H., et al., “The PTH/PTHrP receptor: one receptor for two ligands,” inGenetics of Endocrine and Metabolic Disorders, Thakker, R., ed., Chapman & Hall, London (1997), pp. 389-420). In renal and osteoblastic cell lines, PTH triggers several parallel intracellular signaling responses, including activation of adenylyl cyclase (AC), protein kinase A (PKA), phospholipase C (PLC) and protein kinase C (PKC) and generation of second messengers such as cyclic AMP (cAMP), inositol trisphosphate (IP3), diacylglycerol and increased cytosolic free calcium (Cai ++) (Abou-Samra, A. B., et al., Proc. Natl. Acad. Sci. U.S.A. 89(7):2732-2736 (1992); Azarani, A., et al., J. Biol. Chem. 271(25):14931-14936(1996); Bringhurst, F. R., et al., Endocrinology 132(5):2090-2098 (1993); Civitelli, R., et al., Am. J. Physiol. 255(5 Pt 1):E660-667 (1988); Donahue, H. J., et al., J. Biol. Chem. 263:13522-13527 (1988); Dunlay, R., and Hruska, K., Am. J. Physiol. 258(2 Pt 2):F223-231 (1990); Fujimori, A., et al., Endocrinology 128(6):3032-3039 (1991); Fujimori, A., et al., Endocrinology 130(1):29-36 (1992); Guo, J., et al., Endocrinology 136(9):3884-3891 (1995); Janulis, M., et al., Endocrinology 133:713-719 (1993); Jouishomme, H., et al., J. Bone Miner. Res. 9(6):943-949 (1994); Juppner, H., et al., Science 254(5034):1024-1026 (1991); Pines, M., et al., Bone 18(4):381-389 (1996); Seuwen, K., et al., Brit. J. Pharm. 114(8):1613-1620 (1995); Siegfried, G., et al., Endocrinology 136(3):1267-1275 (1995).
- To date, two structurally related but distinct species of PTH receptors have been cloned (Abou-Samra, A. B., et al.,Proc. Natl. Acad. Sci. U.S.A. 89(7):2732-2736 (1992); Usdin, T. B., et al., J. Biol. Chem. 270(26):15455-15458 (1995); Schipani, E., et al., Endocrinology—132(5):2157-2165 (1993)). The first of these, type A, was isolated from both bone and kidney cells and shown to transduce multiple signaling responses to PTH-(1-34) or PTHrP(1-36) when heterologously expressed in cells that lack
endogenous type 1 PTH/PTHrP receptors (PTHRs) (Abou-Samra, A. B., et al., Proc. Natl. Acad Sci. U.S.A. 89(7):2732-2736 (1992); Azarani, A., et al., J. Biol. Chem. 271(25): 14931-14936 (1996); Bringhurst, F. R., et al., Endocrinology 132(5):2090-2098 (1993); Guo, J., et al., Endocrinology 136(9):3884-3891 (1995); Pines, M., et al., Bone 18(4):381-389 (1996); Jobert, A.-S., et al., Endocrinology 138(12):5282-5292 (1997); Schneider, H., et al., Eur. J. Pharm. 246(2):149-155 (1993)). - Previous efforts to define the contributions of specific regions of the PTH molecule to its binding and signaling properties have been undertaken mainly by use of complex in vivo bioassays, organ cultures, isolated cell membranes or cell lines, generally of rodent origin, that may express more than one type of endogenous PTH receptors (Janulis, M., et al.,Endocrinology 133:713-719 (1993); Siegfried, G., et al., Endocrinology 136(3):1267-1275 (1995); Yamamoto, S., et al., Endocrinology 138:2066-2072 (1997); Jouishomme, H., et al., Endocrinology 130(1):53-60 (1992); Segre, G. V., et al., J. Biol. Chem. 254:6980-6986 (1979); Tregear, G. W., and Potts, J. T., Jr. Endocr. Res. Commun. 2:561-567 (1975); Takasu, H., et al., Endocrinology 137(12):5537-5543 (1996); Orloff, J. J., et al., Am. J. Physiol. 262(5 Pt 1):E599-607 (1992)). For example, relatively few modifications have been made to the extreme amino terminus of PTH: Synthetic [desamino-Ala-1]bPTH-(1-34) was disclosed by Tregear et al. (Endocr. Res. Commun. 2:561-570, page 566 (1975)), by Goltzmann et al. (J. Biol. Chem. 250:3199-3203, (1975)), and by Parsons et al. (Pharmacology of parathyroid hormone and some of its fragments and analogues. In: Talamage R V, Owen M, Parsons J A (Eds.) Calcium-Regulating Hormones. American Elsevier, New York, pp 33-39 (1975)); synthetic [desamino Ser1]-hPTH(1-34) was disclosed by Tregear et al. (Endocr. Res. Commun. 2:561-570 (1975)) and by Rixon et al. (J. Bone and Mineral Res. 9: 1179-1189 (1994)); synthetic 1-desamino-hPTH-(1-31) was disclosed by Rixon et al. (J. Bone and Mineral Res. 9: 1179-1189, (1994))and synthetic [Ala1]-hPTH(1-34), and [Gly1]-hPTH(1-34) were disclosed by Tregear et al. (Endocr. Res. Commun. 2:561-570, page 563 (1975)).
- Early structure/function studies of bovine PTH-(1-34), performed with isolated renal membranes, identified the key role of the carboxyl(C)-terminal bPTH-(25-34) region for receptor binding and of the amino(N)-terminus (i.e., Ser1) for AC activation (Segre, G. V., et al., J. Biol. Chem. 254:6980-6986 (1979); Tregear, G. W., and Potts, J. T., Jr. Endocr. Res. Commun. 2:561-567 (1975)). Later work conducted in vitro with intact renal tubules or with cultured renal or bone cells, however, indicated that N-truncated analogs such as PTH-(3-34), although unable to stimulate AC, could fully activate PKC and could regulate certain PKC-dependent distal biologic responses (Janulis, M., et al., Endocrinology 133:713-719 (1993); Siegfried, G., et al., Endocrinology 136(3):1267-1275 (1995); Jouishomme, H., et al., Endocrinology 130(1):53-60 (1992)). Amino-truncated analogs of PTH-(1-34) also were found to increase PLC activity or Cai ++ in some cells (Donahue, H. J., et al., J. Biol. Chem. 263:13522-13527 (1988); Fujimori, A., et al., Endocrinology 128(6):3032-3039 (1991); Siegfried, G., et al., Endocrinology 136(3):1267-1275 (1995)) though not in others (Reid, I. R., et al., Am. J. Physiol. 253(1 Pt 1):E45-51 (1987); Tamura, T., et al., Biochem. Biophys.,,Res. Commun. 159:1352-1358 (1989)). Studies of the signaling properties of the cloned type I PTHR have focused almost exclusively upon activation of AC, PLC or Cai ++ (Abou-Samra, A. B., et al., Proc. Natl. Acad. Sci. U.S.A. 89(7):2732-2736 (1992); Bringhurst, F. R., et al., Endocrinology 132(5):2090-2098 (1993); Guo, J., et al., Endocrinology 136(9):3884-3891 (1995); Pines, M., et al., Bone 18(4):381-389 (1996); Jobert, A.-S., et al., Endocrinology 138(12):5282-5292 (1997); Schneider, H., et al., Eur. J. Pharm. 246(2):149-155 (1993)), although stimulation of PKC and of PKC-dependent ion transport by hPTH(1-34), hPTH-(3-34) and other hPTH fragments was reported in CHO cells transfected with rat PTHR cDNA (Azarani, A., et al., J. Biol. Chem. 271(25):14931-14936 (1996)).
- Collectively, these observations have engendered the concept that the structural determinants for activation of AC/PKA signaling are distinct from those required for activation of PLC or PKC and that these reside, respectively, within the N- and C-terminal domains of PTH-(1-34) (Jouishomme, H., et al.,J. Bone Miner. Res. 9(6):943-949 (1994); Tregear, G. W., and Potts, J. T., Jr. Endocr. Res. Commun. 2:561-567 (1975); Whitfield, J. F., and Morley, P. Trends Pharm. Sci. 16(11):382-386 (1995)). In particular, the region hPTH-(29-32) was identified specifically as a critical PKC activation domain (Jouishomme, H., et al., J. Bone Miner. Res. 9(6):943-949 (1994); Whitfield, J. F., and Morley, P. Trends Pharm. Sci. 16(11):382-386 (1995)).
- Compared with what is known from these studies of the rat PTHR, much less information is available regarding the structural features of human PTH required for binding to the human PTHR or for activation of its various signaling modes. Alanine-scanning mutagenesis has highlighted the importance of the C-terminal portion of hPTH-(1-34) for binding to the rat PTHR (30). Functional studies of transfected human PTHRs in COS-7 or HEK 293 cells have confirmed that hPTH-(1-34) activates AC and Cai ++, although stimulation of PLC was not observed consistently and responses that were reported were modest (Pines, M., et al., Bone 18(4):381-389 (1996); Seuwen, K., et al., Brit. J. Pharm. 114(8):1613-1620 (1995); Jobert, A.-S., et al., Endocrinology 138(12):5282-5292 (1997); Schneider, H., et al., FEBS Lett. 351(2):281-285 (1994);). The effects of hPTH-(3-34) on Cai ++ are similarly controversial (Pines, M., et al., Bone 18(4):381-389 (1996); Jobert, A.-S., et al., Endocrinology 138(12):5282-5292 (1997)), while the roles of other regions of the hPTH-(1-34) molecule in signaling via the human PTHR have not been systematically addressed. Synthetic hPTH-(1-30)NH2, hPTH-(1-29)NH2, hPTH-(1-28)NH2, hPTH-(1-27)NH2, and hpTH-(1-26)NH2 were each incapable of stimulating the activity of membrane-bound PKCs in osteoblast-like ROS17/2 cells (Neugebauer et al. (Biochem 34: 8835-8842 (1995)).
- The relatively large size of native PTH presents challenges to the use of these peptides as treatments for osteoporosis. In general, a protein of this size is not suitable for use as a drug, since it cannot be delivered effectively by simple methods such as nasal inhalation. Instead, injection is required, and in the case of PTH, daily, or almost daily injections would most likely be needed to achieve increases in bone formation rates. Additionally, larger peptides are technically difficult and expensive to prepare by conventional synthetic chemistry methods. Alternative methods employing recombinant DNA and cell-based expression systems are also expensive, potentially vulnerable to contamination by foreign proteins and do not circumvent the delivery problem.
- Accordingly, it would be advantageous for those skilled in the art to be able to identify a small molecule analog (either peptide or non-peptide) that is based on the larger peptide and yet which still retains the desired biological activities. The activity is greater relative to the intact peptide, but further optimization can lead to enhanced efficacy and potency.
- We recently observed that hPTH-(1-31), shown by others to be a full AC agonist but to be incapable of activating PKC via rodent PTHRs (Jouishomme, H., et al.,Endocrinology 130(1):53-60 (1992)), was as potent as hPTH-(1-34) in activating both AC and PLC via human PTHRs expressed in LLC-PK1, COS-7 or HEK 293 cells (Takasu, H., and Bringhurst, F. R., Endocrinology 139(10):4293-4299 (1998)). These unexpected observations prompted us to undertake a more detailed analysis of the relative roles of the extreme N-terminal region of hPTH-(1-34) in binding to, and selective activation of the human PTH-1/PTH-2 receptor, with a particular focus on PLC activation.
- The present invention is directed to amino terminal modifications of human parathyroid hormone 1-34 peptide which selectively activate the PTH-2 receptor much more effectively than does the native hPTH(1-34)NH2 ligand but which still activate the classical, PTH-1 receptor, albeit at a reduced level. This unexpected finding has important implications for the design of excellent receptor selective PTH agonists in systems including in vivo where both receptors are expressed. Importantly, the desamino peptides of the present invention are still signal selective via the PTH-1 receptor in that they possess some cAMP activity but minimal PLC activity. Accordingly, the desamino peptides described herein will be useful as bone anabolic agents for the therapeutic treatment of bone disease in vivo.
- The present invention relates to PTH(1-34) peptides and derivatives thereof. Compounds of the invention which include PTH(1-34) peptides, fragments thereof, derivatives thereof, pharmaceutically acceptable salts thereof, and N- or C-derivatives thereof, are hereinafter collectively referred to as “compounds of SEQ ID NO:1 and derivatives thereof.”
- The invention provides synthetic and/or recombinant biologically active peptide derivatives of PTH(1-34). In one specific embodiment, this invention provides a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula:
- (a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe(SEQ ID NO:1);
- (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
- (c) pharmaceutically acceptable salts thereof; or
- (d) N- or C-derivatives thereof;
- wherein:
- X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31 )NH2 or desamino Ser1 hPTH(1-34)NH2.
- In accordance with yet a further aspect, this invention also provides pharmaceutical compositions comprising a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula:
- (a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe(SEQ ID NO:1);
- (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
- (c) pharmaceutically acceptable salts thereof; or
- (d) N- or C-derivatives thereof;
- wherein:
- X01 is desamino Ser, desamino Ala or desamino Gly; and a pharmaceutically acceptable carrier.
- In accordance with yet a further aspect, this invention provides a nucleic acid molecule consisting essentially of a polynucleotide encoding a biologically active peptide which has an amino acid sequence selected from the group consisting of:
- (a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsn SerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1);
- (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
- wherein:
- X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2.
- In accordance with yet a further aspect, this invention provides a recombinant DNA molecule comprising: (1) an expression control region, said region in operable linkage with (2) a polynucleotide sequence coding for a biologically active peptide, wherein said peptide is selected from the group consisting of:
- (a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsn SerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1);
- (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
- wherein:
- X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-3)NH2 or desamino Ser1 hPTH(1-34)NH2.
- In accordance with yet a further aspect, this invention provides a method for treating mammalian conditions characterized by decreases in bone mass, which method comprises administering to a subject in need thereof an effective bone mass-increasing amount of a biologically active peptide, wherein said peptide comprises an amino acid sequence at least 90% identical to a member selected from the group consisting essentially of:
- (a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsn SerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1);
- (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
- (c) pharmaceutically acceptable salts thereof; or
- (d) N- or C-derivatives thereof;
- wherein:
- X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2; and a pharmaceutically acceptable carrier.
- In accordance with yet a further aspect, there is provided a method for treating a medical disorder that results from altered or excessive action of the PTH-2 receptor, comprising administering to a patient a therapeutically effective amount of a biologically active peptide wherein said peptide comprises an amino acid sequence at least 90% identical to a member selected from the group consisting essentially of:
- (a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsn SerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1);
- (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
- (c) pharmaceutically acceptable salts thereof; or
- (d) N- or C-derivatives thereof;
- wherein:
- X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2; and a pharmaceutically acceptable carrier sufficient to activate the PTH-2 receptor but not the PTH-1 of said patient.
- In accordance with yet a further aspect, this invention also provides a method for determining rates of bone reformation, bone resorption and/or bone remodeling comprising administering to a patient an effective amount of a labeled peptide of SEQ ID NO: 1 or a derivative thereof and determining the uptake of said peptide into the bone of said patient. The peptide may be labeled with a label selected from the group consisting of: radiolabel, flourescent label, bioluminescent label, or chemiluminescent label. An example of a suitable radiolabel is99mTc.
- In accordance with yet a further aspect of the invention, any amino-acid substitutions at positions 1-34, and more particularly those amino acid substitutions at
amino acid position 1, which do not destroy the biological activity of the PTH(1-34) peptide analog to selectively agonize the PTH-1/PTH-2 receptor (as determined by assays known to the skilled artisan and discussed below), are also included within the scope of the present invention. - FIG. 1 Measurements of cyclic AMP accumulation in HKRK C53 cells. These are LLC-PK1 porcine renal cells, which stably express approximately 150,000 recombinant hPTH-1 receptors per cell. Data are presented for two concentrations of peptide (10−9M(□) and 10−7M (▪). It can be seen that the Ala1- and Gly1-substituted hPTH(1-34)NH2 molecules have nearly the same efficacy in this assay as does native hPTH(1-34)NH2, whereas their desamino counterparts have greatly reduced activity, particularly noticeable at the 1 nM concentration. The peptide hPTH(2-34) has similarly reduced activity via the PTH-1 receptor.
- FIG. 2 cAMP measurements in SaOS-2 cells. These are transformed human osteosarcoma cells which are known to express relatively few (10,000-20,000 per cell) human PTH-1 receptors. As shown in the figure, the cyclase activity of the [Gly1] (♦) and [Ala1] hPTH(1-34)NH2 (▪) analogs again is comparable to that of the control peptide hPTH(1-34) peptide (), whereas the desamino-[Ala1](□) and -[Gly1](⋄) peptides, like the hPTH(2-34) peptide, display minimal activity, even at very high concentrations (i.e., micromolar).
- FIG. 3 cAMP measurements in clonal LLC-PK1 cells (HPR2-7). Clonal LLC-PK1 cells (HPR2-7) express approximately 250,000 recombinant human PTH-2 receptors per cell. Desamino-[Ala1](□) and -[Gly1](⋄) peptides display enhanced efficacy in comparison with hPTH(1-34)NH2 (), hPTH(2-34) (◯) or their [Ala1](▪) and [Gly1](♦) substituted counterparts. The desamino peptides displayed a substantially greater maximal cyclase activation at very high concentrations (1 micromolar).
- FIG. 4 Measurements of phospholipase C (PLC) activity in LLC-PK cells (HKRK-B7) that stably express approximately 1 million human PTH-1 receptors per cell. Desamino-[Ala1] and -[Gly1] compounds exert no activation of PLC via this receptor, whereas hPTH(1-34)NH2 and [Ala1]hPTH(1-34)NH2 are full agonists. [Gly1]hPTH(1-34)NH2 and hPTH(1-34)NH2 are only partial agonists for PLC activation via the
type 1 hPTH receptor). Human PTH(2-34), like the desamino peptides, is inactive in this assay (1000 nM concentration). - FIG. 5 Phospholipase C activating profiles of these peptides in cells (HPR2-22) that express 1.5 million recombinant human PTH-2 receptors per cell. As seen in the figure, both desamino peptides exert greater maximal activation of phospholipase C at the concentration tested (1,000 nM) than does human PTH (1-34)NH2. Human PTH(2-34), which has activity similar to the desamino peptides via the PTH-1 receptor, is seen to be only a partial agonist in this assay.
- FIG. 6 Radioligand binding of hPTH analogs. The enhanced potency of the desamino peptides for the PTH-2 receptor is associated with a 10-fold higher apparent binding affinity, relative to hPTH(1-34), to that receptor (vs the PTH-1 receptor). As shown in the figure, hPTH(1-34)(), HPTH(2-34)(◯) and the desamino peptides exhibit similar competitive displacement of125I-[Nle8,21]rPTH(1-34) radioligand binding to HKRK B28 cells that express 280,000 recombinant PTH-1 receptors/cell, whereas the desamino compounds are 10-fold more potent in displacing this radioligand from HPR2-7 cells that express the human PTH-2 receptor.
- Definitions
- In the description that follows, a number of terms used in recombinant DNA technology and peptide synthesis are utilized extensively. In order to provide a clear and consistent understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided.
- Cloning vector: A plasmid or phage DNA or other DNA sequence which is able to replicate autonomously in a host cell, and which is characterized by one or a small number of restriction endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without loss of an essential biological function of the vector, and into which a DNA fragment may be spliced in order to bring about its replication and cloning. The cloning vector may further contain a marker suitable for use in the identification of cells transformed with the cloning vector. Markers, for example, provide tetracycline resistance or ampicillin resistance.
- Expression vector: A vector similar to a cloning vector but which is capable of enhancing the expression of a gene which has been cloned into it, after transformation into a host. The cloned gene is usually placed under the control of (i. e., operably linked to) certain control sequences such as promoter sequences. Promoter sequences may be either constitutive or inducible.
- Recombinant Host: According to the invention, a recombinant host may be any prokaryotic or eukaryotic host cell which contains the desired cloned genes on an expression vector or cloning vector. This term is also meant to include those prokaryotic or eukaryotic cells that have been genetically engineered to contain the desired gene(s) in the chromosome or genome of that organism. For examples of such hosts, see Sambrook et al.,Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989). Preferred recombinant hosts are eukaryotic cells transformed with the DNA construct of the invention. More specifically, mammalian cells are preferred.
- Promoter: A DNA sequence generally described as the 5′ region of a gene, located proximal to the start codon. The transcription of an adjacent gene(s) is initiated at the promoter region. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent if the promoter is a constitutive promoter. Examples of promoters include the CMV promoter (InVitrogen, San Diego, Calif.), the SV40, MMTV, and hMTIIa promoters (U.S. Pat. No. 5,457,034), the HSV-1 4/5 promoter (U.S. Pat. No. 5,501,979), and the early intermediate HCMV promoter (WO92/17581). Also, tissue-specific enhancer elements may be employed. Additionally, such promoters may include tissue and cell-specific promoters of an organsim.
- Polynucleotide: This term generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. “Polynucleotides” include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, “polynucleotide” refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications have been made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. “Polynucleotide” also embraces relatively short polynucleotides, often referred to as oligonucleotides.
- Polypeptide: This term refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i. e., peptide isosteres. “Polypeptide” refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. “Polypeptides” include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in the research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. See, for instance,Proteins-Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993 and Wold, F., Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in Posttranslational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter et al., “Analysis for protein modifications and nonprotein cofactors”, Methods in Enzymol. 182:626-646 (1990) and Rattan et al., “Protein Synthesis: Posttranslational Modifications and Aging”, Ann NY Acad Sci 663:48-62 (1992).
- Homologous/Nonhomologous: Two nucleic acid molecules are considered to be “homologous” if their nucleotide sequences share a similarity of greater than 40%, as determined by HASH-coding algorithms (Wilber, W. J. and Lipman, D. J.,Proc. Natl. Acad. Sci. 80:726-730 (1983)). Two nucleic acid molecules are considered to be “nonhomologous” if their nucleotide sequences share a similarity of less than 40%.
- Isolated: A term meaning altered “by the hand of man” from the natural state. If a composition or substance occurs in nature, the isolated form has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated,” as the term is employed herein. Thus, a polypeptide or polynucleotide produced and/or contained within a recombinant host cell is considered isolated for purposes of the present invention. Also intended as an “isolated polypeptide” or an “isolated polynucleotide” are polypeptides or polynucleotides that have been purified, partially or substantially, from a recombinant host cell or from a native source. For example, a recombinantly produced version of compounds of SEQ ID NO:1 and derivatives thereof can be substantially purified by the one-step method described in Smith and Johnson,Gene 67:31-40 (1988).
- Identity: This term refers to a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. “Identity” per se has an art-recognized meaning and can be calculated using published techniques. (See, e.g.:Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term “identity” is well known to skilled artisans (Carillo, H. & Lipton, D., SIAM J Applied Math 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H. & Lipton, D., SIAM J Applied Math 48:1073 (1988). Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., Nucleic Acids Research 12(i):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S. F., et al., J Molec Biol 215:403 (1990)).
- Fragment: A “fragment” of a molecule such as a compound of SEQ ID NO: 1 or derivative thereof is meant to refer to any polypeptide subset of these molecules.
- Functional Derivative: The term “derivatives” is intended to include “variants,” the “derivatives,” or “chemical derivatives” of the molecule. A “variant” of a molecule such as a compound of SEQ ID NO: 1 or derivative thereof is meant to refer to a molecule substantially similar to either the entire molecule, or a fragment thereof. An “analog” of a molecule such as a compound of SEQ ID NO: 1 or derivative thereof is meant to refer to a non-natural molecule substantially similar to either the SEQ ID NO: 1 molecules or fragments thereof.
- A molecule is said to be “substantially similar” to another molecule if the sequence of amino acids in both molecules is substantially the same, and if both molecules possess a similar biological activity. Thus, provided that two molecules possess a similar activity, they are considered variants, derivatives, or analogs as that term is used herein even if one of the molecules contains additional amino acid residues not found in the other, or if the sequence of amino acid residues is not identical.
- As used herein, a molecule is said to be a “chemical derivative” of another molecule when it contains additional chemical moieties not normally a part of the molecule. Such moieties may improve the molecule's solubility, absorption, biological half-life, etc. The moieties may alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, etc. Examples of moieties capable of mediating such effects are disclosed inRemington's Pharmaceutical Sciences (1980) and will be apparent to those of ordinary skill in the art.
- Biological Activity of the Protein: This expression refers to the metabolic or physiologic function of compounds of SEQ ID NO: 1 or derivatives thereof including similar activities or improved activities or those activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said compounds of SEQ ID NO: 1 or derivatives thereof.
- Gene Therapy: A means of therapy directed to altering the normal pattern of gene expression of an organism. Generally, a recombinant polynucleotide is introduced into cells or tissues of the organism to effect a change in gene expression.
- Host Animal: Transgenic animals, all of whose germ and somatic cells contain the DNA construct of the invention. Such transgenic animals are in general vertebrates. Preferred host animals are mammals such as non-human primates, mice, sheep, pigs, cattle, goats, guinea pigs, rodents, e.g. rats, and the like. The term Host Animal also includes animals in all stages of development, including embryonic and fetal stages.
- I. Compounds of SEQ ID NO: 1 and Derivatives Thereof—Structural and Functional Properties
- The significance of this invention relates to the existence of two cloned species of parathyroid hormone receptors, PTH-1 and PTH-2. These two receptors share significant (greater than 50%) sequence homology and clearly are members of a common receptor family. They appear to be expressed in very different tissues, however. Specifically, the PTH-2 receptor is expressed in certain regions of the brain, lung, endothelium and pancreas, among others, whereas the
type 1 receptor is more ubiquitously expressed, especially in kidney and bone. Until now, it has been known only that the PTH-2 receptor was selective for PTH, in that native PTH-related peptide (PTHrP) neither binds to nor activates this receptor. The PTH-2 receptor has been expressed at high levels in homologous cell systems such as HEK kidney cells and shown to signal both adenylyl cyclase and cytosolic free calcium transients. - The discovery has been made that certain amino-terminally modified analogs of hPTH(1-34)NH2, specifically desamino-[Gly1]hPTH(1-34)NH2 and desamino-[Ala1]hPTH(1-34)NH2, activate the PTH-2 receptor much more effectively than does the native hPTH(1-34)NH2 ligand. At the same time, these two peptides activate the classical, PTH-1 receptor albeit at a reduced level. The immediate implication of this discovery is that these amino-modified PTH analogs are selective agonists for the PTH-2 receptor.
- The present invention relates to hPTH(1-34) peptides and derivatives thereof. Compounds of the invention which include hPTH(1-34) peptides, fragments thereof, derivatives thereof, pharmaceutically acceptable salts thereof, and N- or C-derivatives thereof, are hereinafter collectively referred to as “compounds of SEQ ID NO:1 and derivatives thereof.”
- In detail, the invention provides synthetic and/or recombinant biologically active peptide derivatives of hPTH(1-34). In one specific embodiment, this invention provides a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula:
- (a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe(SEQ ID NO:1);
- (b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
- (c) pharmaceutically acceptable salts thereof; or
- (d) N- or C-derivatives thereof;
- wherein:
- X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2 (SEQ ID NO:8).
- The present invention thus provides a novel hPTH (1-34) derivative that is a potent selective PTH-2 receptor agonist. In a preferred embodiment, the hPTH (1-34) derivative is altered at
residue 1. Most preferably, the invention includes an hPTH (1-34) derivative having an amino acid substitution of desamino alanine or desamino glycine for serine atposition 1 of hPTH (1-34). - In addition, any other amino-acid substitutions of a nature, which do not destroy the ability of the HPTH (1-34) derivative to selectively agonize the PTH-1/PTH-2 receptor (as determined by assays known to the skilled artisan and discussed below), are included in the scope of the present invention.
- As protein products, compounds of SEQ ID NO: 1 or derivatives thereof of the present invention are amenable to production by the technique of solution- or solid-phase peptide synthesis. The solid phase peptide synthesis technique, in particular, has been successfully applied in the production of human PTH and can be used for the production of compounds of SEQ ID NO: 1 or derivatives thereof of the present invention (for guidance, see Kimura et al., supra, and see Fairwell et al.,Biochem. 22:2691 (1983)). Success with producing human PTH on a relatively large scale has been reported by Goud et al., in J. Bone Min. Res. 6(8):781 (1991), incorporated herein by reference. The synthetic peptide synthesis approach generally entails the use of automated synthesizers and appropriate resin as solid phase, to which is attached the C-terminal amino acid of the desired compounds of SEQ ID NO: 1 or derivatives thereof. Extension of the peptide in the N-terminal direction is then achieved by successively coupling a suitably protected form of the next desired amino acid, using either FMOC- or BOC-based chemical protocols typically, until synthesis is complete. Protecting groups are then cleaved from the peptide, usually simultaneously with cleavage of peptide from the resin, and the peptide is then isolated and purified using conventional techniques, such as by reversed phase HPLC using acetonitrile as solvent and tri-fluoroacetic acid as ion-pairing agent. Such procedures are generally described in numerous publications and reference may be made, for example, to Stewart and Young, “Solid Phase Peptide Synthesis,” 2nd Edition, Pierce Chemical Company, Rockford, Ill. (1984). It will be appreciated that the peptide synthesis approach is required for production of SEQ ID NO: 1 and derivatives thereof variants which incorporate amino acids that are not genetically encoded.
- In accordance with another aspect of the present invention, substituents may be attached to the free amine of the N-terminal amino acid of compounds of SEQ ID NO: 1 or derivatives thereof by standard methods known in the art. For example, alkyl groups, e.g., C1-12 alkyl, may be attached using reductive alkylation. Hydroxyalkyl groups, e.g. C1-12 hydroxyalkyl, may also be attached using reductive alkylation wherein the free hydroxy group is protected with a t-butyl ester. Acyl groups, e.g., COE1, may be attached by coupling the free acid, e.g., E1COOH, to the free amino of the N-terminal amino acid. Also contemplated within the scope of this invention are those compounds of SEQ ID NO:1 and derivatives thereof that alter secondary or tertiary structure, or stability of compounds of SEQ ID NO: 1 or derivatives thereof which still retain biological activity. Such derivatives might be achieved through lactam cyclization, disulfide bonds, or other means known to a person of ordinary skill in the art.
- Among the most preferred embodiments of the invention are those compounds which may serve as selective agonists of the PTH-1/PTH-2 receptor In particular, preferred embodiments are those compounds where X01 is desamino Gly. The amino acid sequence of this preferred embodiment is thus desaminoGlyValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO: 2) or derivatives thereof. [[desaminoGly1]hPTH(1-34)].
- Another set of the preferred embodiments are those compounds having a one amino acid deletion at the carboxy terminus of SEQ ID NO: 2 where X01 is desamino Gly. The amino acid sequence of this preferred embodiment is thus desaminoGlyValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsn (SEQ ID NO: 3) or derivatives thereof. [[desaminoGly1]hPTH(1-33)].
- Another set of the preferred embodiments are those compounds having a seven amino acid deletion at the carboxy terminus of SEQ ID NO: 2 where X01 is desamino Gly. The amino acid sequence of this preferred embodiment is thus desaminoGlyValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLys (SEQ ID NO: 4) or derivatives thereof. [[desaminoGly1]hPTH(1-27)].
- Another set of the preferred embodiments are those compounds where X01 is desamino Ala. The amino acid sequence of this preferred embodiment is thus desaminoAlaValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO: 5) or derivatives thereof. [[desaminoAla1]hPTH(1-34)].
- Another set of the preferred embodiments are those compounds having a one amino acid deletion at the carboxy terminus of SEQ ID NO: 5 where X01 is desamino Ala. The amino acid sequence of this preferred embodiment is thus desaminoAlaValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsn (SEQ ID NO: 6) or derivatives thereof. [[desaminoAla1]hPTH(1-33)].
- Another set of the preferred embodiments are those compounds having a seven amino acid deletion at the carboxy terminus of SEQ ID NO: 5 where X01 is desamino Ala. The amino acid sequence of this preferred embodiment is thus desaminoAlaValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLys (SEQ ID NO: 7) or derivatives thereof. [[desaminoAla1]hPTH(1-27)].
- Another set of the preferred embodiments are those compounds having a one amino acid deletion at the carboxy terminus of SEQ ID NO: 8 where X01 is desamino Ser. The amino acid sequence of this preferred embodiment is thus desamino SerValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsn (SEQ ID NO: 9) or derivatives thereof. [[desaminoSer1]hPTH(1-33)].
- Another set of the preferred embodiments are those compounds having a seven amino acid deletion at the carboxy terminus of SEQ ID NO: 8 where X01 is desamino Ser. The amino acid sequence of this preferred embodiment is thus desaminoSerValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLys (SEQ ID NO: 10) or derivatives thereof. [[desaminoSer1]hPTH(1-27)].
- III. Vectors, Host Cells, and Recombinant Expression
- The present invention also relates to vectors that comprise a polynucleotide of the present invention, and host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of present invention.
- For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) such as calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.
- Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci,E. coli, Streptomyces and Bacillus subtilis cells; fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.
- A great variety of expression systems can be used. Such systems include, among others, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses, and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., Molecular Cloning: A Laboratory Manual (supra).
- RNA vectors may also be utilized for the expression of the nucleic acids encoding compounds of SEQ ID NO: 1 or derivatives thereof disclosed in this invention. These vectors are based on positive or negative strand RNA viruses that naturally replicate in a wide variety of eukaryotic cells (Bredenbeek, P. J. & Rice, C. M.,Virology 3: 297-310, 1992). Unlike retroviruses, these viruses lack an intermediate DNA life-cycle phase, existing entirely in RNA form. For example, alpha viruses are used as expression vectors for foreign proteins because they can be utilized in a broad range of host cells and provide a high level of expression; examples of viruses of this type include the Sindbis virus and Semliki Forest virus (Schlesinger, S., TIBTECH 11:18-22, 1993; Frolov, I., et al., Proc. Natl. Acad. Sci. (USA) 93: 11371-11377, 1996). As exemplified by Invitrogen's Sinbis expression system, the investigator may conveniently maintain the recombinant molecule in DNA form (pSinrep5 plasmid) in the laboratory, but propagation in RNA form is feasible as well. In the host cell used for expression, the vector containing the gene of interest exists completely in RNA form and may be continuously propagated in that state if desired.
- For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment appropriate secretion signals may be incorporated into the desired polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.
- The expression of a DNA sequence requires that the DNA sequence be “operably linked” to DNA sequences which contain transcriptional and translational regulatory information. An operable linkage is a linkage in which the control or regulatory DNA sequences and the DNA sequence sought to be expressed are connected in such a way as to permit gene expression. The precise nature of the “control regions” needed for gene expression may vary from organism to organism, but shall in general include a promoter region which, in prokaryotic cells, contains both the promoter (which directs the initiation of RNA transcription) as well as DNA sequences which, when transcribed into RNA, will signal the initiation of protein synthesis. Regulatory regions in eukaryotic cells will in general include a promoter region sufficient to direct the initiation of RNA synthesis.
- Two DNA sequences are said to be operably linked if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frameshift mutation, (2) interfere with the ability of the promoter region sequence to direct the transcription of the fusion protein-encoding sequence or (3) interfere with the ability of the fusion protein-encoding sequence to be transcribed by the promoter region sequence. Thus, a promoter region would be operably linked to a DNA sequence if the promoter were capable of transcribing that DNA sequence.
- The joining of various DNA fragments, to produce the expression vectors of this invention is performed in accordance with conventional techniques, employing blunt-ended or staggered-ended termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkali and phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases. In the case of a fusion protein, the genetic construct encodes an inducible promoter which is operably linked to the 5′ gene sequence of the fusion protein to allow efficient expression of the fusion protein.
- To express compounds of SEQ ID NO: 1 or derivatives thereof in a prokaryotic cell (such as, for example,E. coli, B. subtilis, Pseudomonas, Streptomyces, etc.), it is necessary to operably link the SEQ ID NO: 1-encoding DNA sequence to a functional prokaryotic promoter. Such promoters may be either constitutive or, more preferably, regulatable (i.e., inducible or derepressible). Examples of constitutive promoters include the int promoter of bacteriophage λ, the bla promoter of the β-lactamase gene of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene of pBR325, etc. Examples of inducible prokaryotic promoters include the major right and left promoters of bacteriophage λ, (PL and PR), the trp, recA. lacZ. lac. and gal promoters of E. coli, the α-amylase (Ulmanen, I. et al., J. Bacteriol. 162:176-182 (1985)), and the σ-28-specific promoters of B. subtilis (Gilman, M. Z. et al., Gene 32:11-20 (1984)), the promoters of the bacteriophages of Bacillius (Gryczan, T. J., In: The Molecular Biology of the Bacilli, Academic Press, Inc., NY (1982)), and Streptomyces promoters (Ward, J. M. et al., Mol. Gen. Genet. 203:468-478 (1986)). Prokaryotic promoters are reviewed by Glick, B. R., J. Ind. Microbiol. 1:277-282 (1987); Cenatiempo, Y., Biochimie 68:505-516 (1986)); and Gottesman, S., Ann. Rev. Genet. 18:415-442(1984)).
- If expression is desired in a eukaryotic cell, such as yeast, fungi, mammalian cells, or plant cells, then it is necessary to employ a promoter capable of directing transcription in such a eukaryotic host. Preferred eukaryotic promoters include the promoter of the mouse metallothionein I gene (Hamer, D. et al.,J. Mol. Appl. Gen. 1:273-288 (1982)); the TK promoter of Herpes virus (McKnight, S., Cell 31:355-365 (1982)); the SV40 early promoter (Benoist, C., et al., Nature (London) 290:304-310 (1981)); and the yeast ga14 gene promoter (Johnston, S. A., et al., Proc. Natl. Acad. Sci. (USA) 79:6971-6975 (1982); Silver, P. A., et al., Proc. Natl. Acad. Sci. (USA) 81:5951-5955 (1984)).
- Preferably, the introduced DNA sequence will be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Any of a wide variety of vectors may employed for this purpose. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to “shuttle” the vector between host cells of different species.
- Preferred prokaryotic vectors include, without limitation, plasmids such as those capable of replication inE. coli (such as, for example, pBR322, ColEl , pSC101, pACYC 184, πVX. Such plasmids are, for example, disclosed by Maniatis, T., et al., In: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1982)). Preferred plasmid expression vectors include the pGFP-1 plasmid described in Gardella et al., J. Biol. Chem. 265:15854-15859 (1989), or a modified plasmid based upon one of the pET vectors described by Studier and Dunn, Methods in Enzymology 185: 60-89 (1990). Bacillus plasmids include pC194, pC221, pT127, etc. Such plasmids are disclosed by Gryczan, T. In: The Molecular Biology of the Bacilli, Academic Press, NY pp. 307-329 (1982). Suitable Streptomyces plasmids include pIJIOI (Kendall, K. J. et al., J. Bacteriol. 169:4177-4183 (1987)), and streptomyces bacteriophages such as φC31 (Chater, K. F. et al., In: Sixth International Symposium on Actinomycetales Biology, Akademiai Kaido, Budapest, Hungary, pp. 45-54 (1986)). Pseudomonas plasmids are reviewed by John, J. F. et al., Rev. Infect. Dis. 8:693-704 (1986)), and Izaki, K., Jon. J. Bacteriol. 33:729-742 (1978)).
- Preferred eukaryotic expression vectors include, without limitation, BPV, vaccinia, 2-micron circle, etc. Such expression vectors are well known in the art (Botstein, D., et al.,Miami Wntr. Symp. 19:265-274 (1982); Broach, J. R., In: The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. pp. 445-470 (1981); Broach, J. R., Cell 28:203-204 (1982); Bollon, D. P., et al., J. Clin. Hematol. Oncol. 10:39-48 (1980); Maniatis, T., In: Cell Biology: A Comprehensive Treatise, Vol. 3, Gene Expression, Academic Press, NY, pp. 563-608 (1980)).
- In addition to microorganisms, cultures of cells derived from multicellular organisms may also be used as hosts. In principle, any such cell culture is workable, whether from vertebrate or invertebrate cellular sources. Interest, however, has been greater with cells from vertebrate sources. Examples of useful vertebrate host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, WI38, BHK, COS-7, and MDCK cell lines. Expression vectors for such cells ordinarily include (if necessary) an origin of replication, a promoter located in front of or upstream to the gene to be expressed, along with any necessary ribosome binding sites, RNA splice sites, polyadenylation site, and transcriptional terminator sequences.
- For use in mammalian cells, the control functions on the expression vectors are often provided by viral material. For example, commonly used promoters are derived from polyoma,
Adenovirus 2, Simian Virus 40 (SV40) and cytomegalovirus. The early and late promoters of SV40 virus are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication (Fiers et al., Nature 273:113 (1978)). - An origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g. Polyoma, Adeno, VSV, BPV) source or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.
- If cells without formidable cell membrane barriers are used as host cells, transfection is carried out by the calcium phosphate precipitation method as described by Graham and Van der Erb, Virology 52:546 (1978). However, other methods for introducing DNA into cells, such as by nuclear injection or by protoplast fusion may also be used. In the case of gene therapy, the direct naked plasmid or viral DNA injection method, with or without transfection-facilitating agents such as, without limitation, liposomes, provides an alternative approach to the current methods of in vivo or in vitro transfection of mammalian cells. If prokaryotic cells or cells which contain substantial cell wall constructions are used, the preferred method of transfection is calcium treatment, using calcium chloride as described in Cohen et al.,Proc. Natl. Acad. Sci. USA 69:2110 (1972).
- IV. Administration and Therapeutic Utility of Compounds of SEQ ID NO:1 or Derivatives Thereof
- (A) Administration of Compounds of SEQ ID NO:1 or Derivatives Thereof
- In general, compounds of SEQ ID NO: 1 or derivatives thereof of this invention, or salts thereof, are administered in amounts between about 0.01 and 1 μg/kg body weight per day, preferably from about 0.07 to about 0.2 μg/kg body weight per day. For a 50 kg human female subject, the daily dose of biologically active compounds of SEQ ID NO: 1 or derivatives thereof is from about 0.5 to about 50 μgs, preferably from about 3.5 to about 10 μgs. In other mammals, such as horses, dogs, and cattle, higher doses may be required. This dosage may be delivered in a conventional pharmaceutical composition by a single administration, by multiple applications, or via controlled release, as needed to achieve the most effective results, preferably one or more times daily by injection. Most preferably, this dosage may be delivered in a conventional pharmaceutical composition by nasal insufflation.
- The selection of the exact dose and composition and the most appropriate delivery regimen will be influenced by, inter alia, the pharmacological properties of the selected compounds of SEQ ID NO: 1 or derivatives thereof, the nature and severity of the condition being treated, and the physical condition and mental acuity of the recipient.
- Representative preferred delivery regimens include, without limitation, oral, parenteral (including subcutaneous, transcutaneous, intramuscular and intravenous), rectal, buccal (including sublingual), transdermal, and intranasal insufflation.
- Pharmaceutically acceptable salts retain the desired biological activity of the compounds of SEQ ID NO: 1 or derivatives thereof without toxic side effects. Examples of such salts are (a) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acids, naphthalene disulfonic acids, polygalacturonic acid and the like; (b) base addition salts formed with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, and the like; or with an organic cation formed from N,N′-dibenzylethylenediamine or ethylenediamine; or (c) combinations of (a) and (b), e.g., a zinc tannate salt and the like.
- A further aspect of the present invention relates to pharmaceutical compositions comprising as an active ingredient compounds of SEQ ID NO: 1 or derivatives thereof of the present invention, or pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable, non-toxic carrier. As mentioned above, such compositions may be prepared for parenteral (subcutaneous, transcutaneous, intramuscular or intravenous) administration, particularly in the form of liquid solutions or suspensions; for oral or buccal administration, particularly in the form of tablets or capsules; for rectal, transdermal administration; and for intranasal administration, particularly in the form of powders, nasal drops or aerosols.
- The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example as described in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., (1985), incorporated herein by reference. Formulations for parenteral administration may contain as excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like. For oral administration, the formulation can be enhanced by the addition of bile salts or acylcarnitines. Formulations for nasal administration may be solid and may contain excipients, for example, lactose or dextran, or may be aqueous or oily solutions for use in the form of nasal drops or metered spray. For buccal administration typical excipients include sugars, calcium stearate, magnesium stearate, pregelatinated starch, and the like.
- When formulated for the most preferred route of administration, nasal administration, the absorption across the nasal mucous membrane may be enhanced by surfactant acids, such as for example, glycocholic acid, cholic acid, taurocholic acid, ethocholic acid, deoxycholic acid, chenodeoxycholic acid, dehydrocholic acid, glycodeoxycholic acid, cyclodextrins and the like in an amount in the range between about 0.2 and 15 weight percent, preferably between about 0.5 and 4 weight percent, most preferably about 2 weight percent.
- Delivery of the compounds of the present invention to the subject over prolonged periods of time, for example, for periods of one week to one year, may be accomplished by a single administration of a controlled release system containing sufficient active ingredient for the desired release period. Various controlled release systems, such as monolithic or reservoir-type microcapsules, depot implants, osmotic pumps, vesicles, micelles, liposomes, transdermal patches, iontophoretic devices and alternative injectable dosage forms may be utilized for this purpose. Localization at the site to which delivery of the active ingredient is desired is an additional feature of some controlled release devices, which may prove beneficial in the treatment of certain disorders.
- One form of controlled release formulation contains the polypeptide or its salt dispersed or encapsulated in a slowly degrading, non-toxic, non-antigenic polymer such as copoly(lactic/glycolic) acid, as described in the pioneering work of Kent, Lewis, Sanders, and Tice, U.S. Pat. No. 4,675,189, incorporated by reference herein. The compounds or, preferably, their relatively insoluble salts, may also be formulated in cholesterol or other lipid matrix pellets, or silastomer matrix implants. Additional slow release, depot implant or injectable formulations will be apparent to the skilled artisan. See, for example, Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson ed., Marcel Dekker, Inc., New York, 1978, and R. W. Baker, Controlled Release of Biologically Active Agents, John Wiley & Sons, New York, 1987, incorporated by reference herein.
- Like PTH, the compounds of SEQ ID NO:1 and derivatives thereof may be administered in combination with other agents useful in treating a given clinical condition. When treating osteoporosis and other bone-related disorders for example, the compounds of SEQ ID NO:1 and derivatives thereof may be administered in conjunction with a dietary calcium supplement or with a vitamin D analog (see U.S. Pat. No. 4,698,328). Alternatively, the compounds of SEQ ID NO:1 and derivatives thereof may be administered, preferably using a cyclic therapeutic regimen, in combination with bisphosphonates, as described for example in U.S. Pat. No. 4,761,406, or in combination with one or more bone therapeutic agents such as, without limitation, calcitonin and estrogen.
- (B) Therapeutic Utility of Compounds of SEQ ID NO: 1 or Derivatives Thereof
- Compounds of SEQ ID NO: 1 or derivatives thereof of this invention are useful for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass. In particular, the compounds of this invention are indicated for the prophylaxis and therapeutic treatment of osteoporosis and osteopenia in humans. Furthermore, the compounds of this invention are indicated for the prophylaxis and therapeutic treatment of other bone diseases. The compounds of this invention are indicated for the prophylaxis and therapeutic treatment of hypoparathyroidism. Finally, the compounds of this invention are indicated for use as agonists for fracture repair and as antagonists for hypercalcemia.
- Some forms of hypercalcemia and hypocalcemia are related to the interaction between PTH and PTHrP and the PTH-1 and PTH-2 receptors. Hypercalcemia is a condition in which there is an abnormal elevation in serum calcium level; it is often associated with other diseases, including hyperparathyroidism, osteoporosis, carcinomas of the breast, lung and prostate, epidermoid cancers of the head and neck and of the esophagus, multiple myeloma, and hypernephroma. Hypocalcemia, a condition in which the serum calcium level is abnormally low, may result from a deficiency of effective PTH, e.g., following thyroid surgery.
- Nucleic acids of the invention which encode compounds of SEQ ID NO: 1 or derivatives thereof may also be linked to a selected tissue-specific promoter and/or enhancer and the resultant hybrid gene introduced, by standard methods (e.g., as described by Leder et al., U.S. Pat. No. 4,736,866, herein incorporated by reference), into an animal embryo at an early developmental stage (e.g. the fertilized oocyte stage), to produce a transgenic animal which expresses elevated levels of compounds of SEQ ID NO: 1 or derivatives thereof in selected tissues (e.g., the osteocalcin promoter for bone). Such promoters are used to direct tissue-specific expression of compounds of SEQ ID NO: 1 or derivatives thereof in the transgenic animal.
- In addition, any other amino-acid substitutions of a nature, which do not destroy the ability of the PTH analog to agonize the PTH-1/PTH-2 receptor (as determined by assays known to the skilled artisan and discussed below), are included in the scope of the present invention.
- By “agonist” is intended a ligand capable of enhancing or potentiating a cellular response mediated by the PTH-1/PTH-2 receptor. Whether any candidate “agonist” of the present invention can enhance or inhibit such a cellular response can be determined using art-known protein ligand/receptor cellular response or binding assays, including those described elsewhere in this application.
- In accordance with yet a further aspect of the invention, there is provided a method for treating osteoporosis, comprising administering to a patient a therapeutically effective amount of a compound of SEQ ID NO: 1 or a derivative thereof, sufficient to selectively activate the PTH-1/PTH-2 receptor of said patient. To administer the agonist, the appropriate compound of SEQ ID NO: 1 or a derivative thereof is used in the manufacture of a medicament, generally by being formulated in an appropriate carrier or excipient such as, e.g., physiological saline, and preferably administered intravenously, intramuscularly, subcutaneously, orally, or intranasally, at a dosage that provides selective activation of the PTH-1/PTH-2 receptor after binding of a compound of SEQ ID NO: 1 or a derivative thereof . Typical dosage would be 1 ng to 10 mg of the peptide per kg body weight per day. Such dosages and administration may be used for administration of a PTH agonist, e.g., for treatment of conditions such as osteoporosis, other metabolic bone disorders, and hypoparathyroidism and related disorders.
- In a preferred embodiment, the compound of SEQ ID NO: 1 or a derivative thereof used in the method has an amino acid substitution of desamino alanine for serine at
amino acid position 1 of compound of SEQ ID NO: 1. In this particular embodiment, the PTH derivative is [desamino Ala1]PTH(1-34)(SEQ ID NO: 5). In another preferred embodiment, the compound of SEQ ID NO: 1 or a derivative thereof used in the method has an amino acid substitution of desamino glycine for serine atamino acid position 1 of compound of SEQ ID NO: 1. In this particular embodiment, the PTH derivative is [desaminoGly1] PTH(1-34). (SEQ ID NO: 2) - V. Receptor-Signaling Activities of Compounds of SEQ ID NO: 1 or Derivatives Thereof
- A crucial step in the expression of hormonal action is the interaction of hormones with receptors on the plasma membrane surface of target cells. The formation of hormone-receptor complexes allows the transduction of extracellular signals into the cell to elicit a variety of biological responses.
- A. Screening for PTH-2 Receptor Agonists
- Polypeptides of the invention may be screened for their agonistic properties using the cAMP accumulation assay. Cells expressing PTH-2 receptor on the cell surface are incubated with native PTH(1-84) for 5-60 minutes at 37° C., in the presence of2 mM IBMX (3-isobutyl-1-methyl-xanthine, Sigma, St. Louis, Mo.). Cyclic AMP accumulation is measured by specific radio-immunoassay, as described above.
- A compound of SEQ ID NO: 1 or a derivative thereof that competes with native PTH(1-84) for binding to the PTH-2 receptor, and which stimulates cAMP accumulation in the presence or absence of native PTH(1-84) is a competitive agonist. A compound of SEQ ID NO: 1 or a derivative thereof that does not compete with native PTH(1-84) for binding to the PTH-2 receptor but which is still capable of stimulating cAMP accumulation in the presence or absence of native PTH(1-84), or which stimulates a higher cAMP accumulation than that observed by a compound of SEQ ID NO: 1 or a derivative thereof alone, would be considered a non-competitive agonist.
- It will be appreciated to those skilled in the art that the invention can be performed within a wide range of equivalent parameters of composition, concentration, modes of administration, and conditions without departing from the spirit or scope of the invention or any embodiment thereof.
- Having now fully described the invention, the same will be more readily understood by reference to specific examples which are provided by way of illustration, and are not intended to be limiting of the invention, unless herein specified.
- Materials and Methods
- Cell Culture
- The following cell lines were used in these studies. HKRK C53 subclones of LLC-PKI porcine renal epithelial cells which stably express human PTH-1 receptors (150,000 receptors/cell). SaOS-2 cells are transformed human osteosarcoma cells which express relatively few (10,000-20,000 per cell) human PTH-1 receptors. HPR2-7 cells are subclones of LLC-PK1 which express approximately 250,000 recombinant human PTH-2 receptors per cell. HKRK-B7 cells are subclones of LLC-PK which stably express approximately 1 million hPTH-1 receptors per cell. HPR2-22 cells are subclones of LLC-PK1 which express 1.5 million recombinant hPTH-2 receptors per cell. The HPR2-27 and HPR2-22 cell lines were created in the same fashion as the HKRK cells but employing instead type 2 PTH receptor cDNA using the transfection technique of (Bringhurst, F. R., el al., Endocrinology 132(5):2090-2098 (1993); Guo, J., et al., Endocrinology 136(9):3884-3891 (1995)).
- All cells were maintained under 5% CO2 in air in Dulbecco's modified essential medium containing 7% fetal bovine serum (FBS) and 1% penicillin/streptomycin (GIBCO-BRL, Grand Island, N.Y.). Cells were seeded into 24-well plates two days before assay at a suitable cell density (approximately 2-2.5×105 cells/well). DNA transfections in COS/HEK cells were performed 24 hr after plating and inositol radiolabel was added 24 hr thereafter (see below). Cell transfections were performed as previously described (Gardella, T. J., et al., Endocrinology 132(5):2024-2030 (1993))
- Radioligand Binding and Signaling Assays
- Intracellular cAMP accumulation, PLC activation and PTHR binding affinity were measured as previously reported (Bringhurst, F. R., et al.,Endocrinology 132(5):2090-2098 (1993); Guo, J., et al., Endocrinology 136(9):3884-3891 (1995)). Intracellular cAMP accumulation was measured in extracts of cells that were exposed to human PTH peptides in the presence of isobutylmethyxanthine (IBMX, 1 mM) at 37° C. for 15 min. After terminating the reactions by aspiration and freezing in liquid nitrogen, cell monolayers were extracted with 50 mM HCl and cAMP was measured using a radioimmunoassay kit (Dupont-New England Nuclear, Boston, Mass.).
- PLC was activated by PTH agonists in the presence of 30 mM LiCl at 37° C; for 30 min after 16 hr of labeling with [3H]myo-inositol (3 uCi/ml) in serum-free medium containing 0.1% bovine serum albumin. The reactions were stopped by rapid aspiration and addition of cold 5% TCA. Water-soluble radiolabeled inositol trisphosphate (IP3) was isolated after ether extraction by ion-exchange chromatography (Guo, J., et al., Endocrinology 136(9):3884-3891 (1995)). In experiments involving HEK 293 cells, cells previously transfected with human PTHR cDNA (in the pcDNA1 expression vector HKRK) using Lipofectamine (Gibco BRL) were labeled with [3H]myo-inositol and assayed as described above, except that total water-soluble [3H]inositol polyphosphates were collected as a single fraction from the ion-exchange columns.
- Radioligand competition binding assays were performed at 2-8° C. for 6 hr using125I-[Nle8,21]rat PTH-(1-34)(100,000 cpm/well) in the presence or absence of non-radioactive hPTH-(1-34) analogs. Cell layers were washed three times before solubilization for determination of cell-associated radioactivity.
- The average levels basally and in the presence of maximal concentrations of hPTH-(1-34) observed in HKRK C53 cells for the assays reported here were 12±4 and 207±37 pmoles/well/15 min for cAMP accumulation, 898±142 and 1908±251 cpm/well for 1P3 formation and 25520±1909 and 956±135 cpm/well for binding, respectively. The average levels basally and in the presence of maximal concentrations of hPTH-(1-34) observed in HKRK B28 cells for the assays reported here were 1.6±0.5 and 337±55 pmoles/well/15 min for cAMP accumulation, and 1497±121 and 16,137±919 cpm/well for binding, respectively. The average levels basally and in the presence of maximal concentrations of hPTH-(1-34) observed in HPR2-7 cells for the assays reported here were 2.5±1.0 and 133±14 pmoles/well/15 min for cAMP accumulation, and 1156±243 and 4541±386 cpm/well for binding, respectively. The average levels basally and in the presence of maximal concentrations of hPTH-(1-34) observed in HPR2-22 cells for the assays reported here were 5.2±0.5 and 286±8 pmoles/well/15 min for cAMP accumulation, and 335±68 cpm/well (basal) for IP3 formation, respectively.
- Peptides and Other Reagents
- All reagents were purchased from Sigma (St. Louis, Mo.), unless otherwise specified. All isotopes were obtained from Dupont-New England Nuclear (Boston, Mass.). Human PTH peptides were synthesized in the Biopolymer Core Laboratory of the Endocrine Unit with C-terminal amidation and, when present, substitution of Tyr34 for the naturally occurring Phe34. [Tyr0]hPTH-(1-34) was purchased from Sigma Co. 125I-[Nle8,21]rat PTH-(1-34) was iodinated and purified as previously described (Bringhurst, F. R., et al., Endocrinology 132(5):2090-2098 (1993); Guo, J., et al., Endocrinology 136(9):3884-3891 (1995)).
- Results
- N-Terminally Modified hPTH Analogs
- We addressed the role of the N-terminal Ser1 residue and of its α-amino group in binding to and activation of the human PTH-1 and PTH-2 receptor. Because earlier work with isolated rat renal membranes had shown that substitution of Ala1 for Ser1 in hPTH-(1-34) increased its AC activity, whereas a Gly1 substitution impaired AC activation by bPTH-(1-34) (Tregear, G. W., and Potts, J. T., Jr. Endocr. Res. Commun. 2:561-567 (1975)), these position-1 modifications were introduced into hPTH-(1-34) and the resultant peptides were used to compare the effect of the modifications at the N-terminus of hpTH(1-34) on binding to, and activation of, these two receptors expressed in the various cell lines tested. The results for measurements of cyclic AMP accumulation are shown in FIGS. 1-3.
- FIG. 1 shows measurements of cyclic AMP accumulation in HKRK C53 cells. There are LLC-PK, porcine renal cells, which stably express approximately 150,000 recombinant hPTH-1 receptors per cell. Data are presented for two concentrations of peptide (10−9M and 10−7M). It can be seen that the Ala1- and Gly1-substituted hPTH(1-34)NH2 molecules have nearly the same efficacy in this assay as native hPTH(1-34)NH2, whereas their desamino counterparts have greatly reduced activity, particularly noticeable at the 1 nM concentration. The peptide hPTH(2-34) has similarly reduced activity via the PTH-1 receptor.
- FIG. 2 shows cAMP measurements in SaOS-2 cells. These are transformed human osteosarcoma cells which are known to express relatively few (10,000-20,000 per cell) human PTH-1 receptors. As shown in FIG. 2, the cyclase activity of the [Gly1] and [Ala1] hPTH(1-34)NH2 analogs again is comparable to that of the control peptide hPTH(1-34)NH2, whereas the desamino anologs, like hPTH(2-34), are very weak agonists at the highest concentration tested (1 uM).
- In contrast to these observations made in cells that express PTH-1 receptors, FIG. 3 demonstrates the cAMP responsiveness to the same peptides when they are added to other clonal LLC-PK1 cells (HPR2-7) that express approximately 250,000 recombinant human PTH-2 receptors per cell. It is evident from FIG. 3 that the desamino-[Ala1] and -[Gly1] peptides display enhanced efficacy in comparison with hPTH(1-34)NH2, hPTH(2-34) or their [Ala1] and [Gly1] substituted counterparts. In addition, the desamino peptides show a substantially greater maximal cyclase activation at very high concentrations (1 micromolar).
- Human PTH-(3-34) had been characterized previously as a PLC/PKC-selective peptide via rodent PTH receptors (Azarani, A., et al.,J. Biol. Chem. 271(25):14931-14936 (1996); Fujimori, A., et al., Endocrinology 128(6):3032-3039 (1991); Jouishomme, H., et al., Endocrinology 130(1):53-60 (1992)). We have observed, however, that this peptide, at concentrations as high as 1000 nM, did not activate PLC in HKRK B7 cells or in COS-7 cells that expressed rat or human PTHRs (Takasu et al., J. Bone Miner. Res., In Press). These results indicated that the first two amino acids at the N-terminus of hPTH-(1-34) (Ser1-Val2) must be important for PLC as well as AC activation via the human PTHR.
- To refine this analysis, we first studied the properties of hPTH-(2-34) in the various cell lines. As shown in FIGS. 4 and 5, hPTH-(2-34) did not elicit PLC activity in HKRK B7 cells, even though its activation of AC was comparable in magnitude and sensitivity to that of hPTH-(1-34). In addition, as shown in FIG. 6, PTH(2-34) also binds as well to the hPTH receptor as does PTH(1-34). Similar results were obtained using COS-7 cells expressing abundant human PTHRs (data not shown). The inability of hPTH-(2-34) to activate PLC via the human PTH-1 receptor was confirmed in a fully homologous system by using HEK-293 human embryonic kidney cells that were transiently transfected with human PTHR cDNA (data not shown).
- We next addressed the effect of the extreme N-terminal amino acid of PTH(1-34) on the activation of the PLC/PKC pathway. FIG. 4 shows measurements of phospholipase C (PLC) activity following addition of the indicated peptides at a final concentration of 1000 nM to LLC-PK cells (HKRK-B7) that stably express approximately 1 million hPTH-1 receptors per cell. As shown in FIG. 4, the desamino-[Ala1] and -[Gly1] compounds exert no activation of PLC via this receptor, whereas hPTH(1-34)NH2 and [Ala1]hPTH(1-34)NH2 are both full agonists. The [Gly1]hPTH(1-34)NH2 substituted peptide showed diminished PLC activity (approximately 50% of the hPTH(1-34) maximum) at the concentration tested and is thus only a partial agonist for PLC activation via this receptor. Human PTH(2-34), like the desamino peptides, is inactive in this assay.
- Shown in FIG. 5, in contrast, are phospholipase C activating profiles of these peptides in HPR 2-22 cells that express 1.5 million recombinant hPTH-2 receptors per cell. As seen in the figure, both the desamino-[Ala1] and -[Gly1] hPTH(1-34) peptides exert greater maximal activation of phospholipase C at the concentration tested (1,000 nM) than does human PTH(1-34)NH2. Human PTH(2-34), which has activity similar to the desamino peptides via the PTH-1 receptor, is seen to be only a partial agonist in this assay.
- As shown in FIG. 6, the enhanced potency of the desamino peptides for the PTH-2 receptor is associated with a 10-fold higher apparent binding affinity, relative to hPTH(1-34), to that receptor (vs the PTH-1 receptor). As shown in the figure, hPTH(1-34), HPTH(2-34) and the desamino peptides exhibit similar competitive displacement of125I-[Nle8,21]rPTH(1-34) radioligand bind to HKRK B28 cells that express 280,000 recombinant human PTH-1 receptors/cell, whereas the desamino compounds are 10-fold more potent in displacing this radioligand from HPR2-7 cells that express the human PTH-2 receptor.
- Discussion
- The findings presented in these experiments require that some key aspects of current models of the structural determinants of PTH-1 and PTH-2 signaling be re-examined. Work conducted previously with rodent and opossum cells that express endogenous PTHRs had shown that N-truncated PTH analogs, such as PTH-(3-34), lack AC activity but nevertheless can potently activate PKC and, in some systems (Donahue, H. J., et al.,J. Biol. Chem. 263:13522-13527 (1988); Fujimori, A., et al., Endocrinology 128(6):3032-3039 (1991); Siegfried, G., et al., Endocrinology 136(3):1267-1275 (1995)), but not others (Reid, I. R., et al., Am. J. Physiol. 253(1 Pt 1):E45-51 (1987); Tamura, T., et al., Biochem. Biophys.,,Res. Commun. 159:1352-1358 (1989)), Cai ++ transients. Detailed analysis of the PKC-activating properties of N- and C-truncated hPTH-(1-34) analogs led to the conclusion that the sequence hPTH-(29-32) represents a critical “PKC activation domain” (Jouishomme, H., et al., J. Bone Miner. Res. 9(6):943-949 (1994); Jouishomme, H., et al., Endocrinology 130(1):53-60 (1992); Whitfield, J. F., and Morley, P. Trends Pharm. Sci. 16(11):382-386 (1995)).
- In order to determine if the PTH-1 and PTH-2 receptors recognize the same structure features of the PTH ligand, we compared the effect of modifications of the N-terminus of hPTH(1-34) on binding to, and activation of, these two receptors. In comparisons between clonal LLC-PK1 cells that stably expressed human PTH-1 vs. human PTH-2 receptors, hPTH(1-34) elicited concentration dependent activation of AC, with EC50s of 1 nM, respectively. Human PTH(2-34) was less active (≦10 fold) via both receptors. Substitution of Ala or Gly for the N-terminal Ser residue of hPTH(1-34) did not alter AC activation via either receptor when tested in cells expressing either 150,000 (HKRK C53) or 10,000-20,000 (SaOS) human PTH-1 receptors per cell. Removal of the α-amino group to produce desamino-[Ala1]hPTH(1-34) or desamino-[Gly1]hPTH(1-34) reduced AC activity via the human PTH-1 receptor by 10-fold. In striking contrast, we found that these desamino peptides activated the human PTH-2 receptor with greatly enhanced potency: the EC50 for both was 3-fold lower (10 nM vs. 30 nM) and the maximal response twice that seen with hPTH(1-34).
- Amino-truncated analogs, including bPTH-(2-34), hPTH-(2-38) and desamino-PTH-(1-34), previously were found to exhibit only weak AC activity when tested in vitro (Fujimori, A., et al.,Endocrinology 128(6):3032-3039 (1991); Fujimori, A., et al., Endocrinology 130(1):29-36 (1992); Tregear, G. W., and Potts, J. T., Jr. Endocr. Res. Commun. 2:561-567 (1975); Rixon, R. H., et al., J. Bone Miner. Res. 9(8):1179-1189 (1994)), whereas we found that hPTH-(2-34), desamino-[Ala1]hPTH-(1-34) and desamino-[Gly1]hPTH-(1-34) were approximately equipotent with hPTH-(1-34). This disparity in AC activation is likely explained by the much larger number of human PTH-1 receptors expressed by the HKRK B7 cells than by the osteosarcoma cells or partially purified membranes used in previous studies (Fujimori, A., et al., Endocrinology 128(6):3032-3039 (1991); Fujimori, A., et al., Endocrinology 130(1):29-36 (1992); Tregear, G. W., and Potts, J. T., Jr. Endocr. Res. Commun. 2:561-567 (1975); Rixon, R. H., et al., J. Bone Miner. Res. 9(8):1179-1189 (1994)).
- The HKRK B7 cells were also selected for these studies to optimize analysis of the structural basis of PLC signaling via human PTHRs, which requires a high level of receptor expression (Guo, J., et al.,Endocrinology 136(9):3884-3891 (1995); Pines, M., et al., Endocrinology 135(4):1713-1716 (1994)). When these N-truncated peptides were tested with other LLC-PKI subclones that expressed fewer human PTHRs (i.e. 100,000-300,000 per cell), their AC responses were indeed reduced by as much as 10-fold, relative to hPTH-(1-34) (data not shown). On the other hand, studies of such N-truncated PTH analogs in vivo have demonstrated greater biopotency than predicted from measures of AC activity in vitro (Tregear, G. W., et al., Endocrinology 93:1349-1353 (1973); Hilliker, S., et al., Bone 19:469-477 (1996)). Also, the actual number of PTH-1 receptors expressed by relevant target cells in vivo remains uncertain but could be within the range studied here (Shukunarni, C., et al., J. Cell Biol. 133(2):457-468 (1996); Bos, M. P., et al., Calcif. Tiss. Internat. 58(2):95-100 (1996)).
- Previous studies of the effects of hPTH-(1-34) or PTH-(3-34) on PLC activation or Cai ++ signaling via recombinant human PTHRs expressed heterologously in COS-7 or HEK-293 cells produced discordant findings (Pines, M., et al., Bone 18(4):381-389 (1996); Seuwen, K., et al., Brit. J. Pharm. 114(8):1613-1620 (1995); Jobert, A.-S., et al., Endocrinology 138(12):5282-5292 (1997); Schneider, H., et al., FEBS Lett. 351(2):281-285 (1994)). Because of the numerous observations that N-terminally truncated PTH analogs trigger activation of PKC and Cai ++ in other systems (Azarani, A., et al, J. Biol. Chem. 271(25):14931-14936 (1996); Donahue, H. J., et al., J. Biol. Chem. 263:13522-13527 (1988); Fujimori, A., et al., Endocrinology 128(6):3032-3039 (1991); Fujimori, A., et al., Endocrinology 130(1):29-36 (1992); Janulis, M., et al., Endocrinology 133:713-719 (1993); Jouishomme, H., et al., Endocrinology 130(I):53-60 (1992); Chakravarthy, B. R., et al, Biochem. Biophys. Res. Commun. 171(3):1105-1110 (1990); Cole, J. A., et al., Endocrinology 1229:2981-2989 (1988); Rixon, R. H., et al., J. Bone Miner. Res. 9(8):1179-1189 (1994)), however, our finding that a free α-amino group at position-1 of hPTH-(1-34) is an absolute requirement for PLC activation via the human PTH-1 receptor was quite unexpected. In fact, our data indicate that PLC activation via the PTH-1 receptor is even more sensitive to such subtle N-terminal modifications than is AC, and, in contrast to the consequences of stepwise C-terminal truncation of hPTH-(1-34)(data not shown), the reduction in PLC potency of these analogs cannot be attributed to lower binding affinity. This suggests that the extreme N-terminus of hPTH-(1-34) constitutes a true “activation domain” for PLC signaling via the human PTH-1 receptor. We should note that others previously have reported activation of PLC by the N-truncated peptides bPTH-(2-34) and bPTH-(3-34) in rat UMR 106-01 osteosarcoma cells (Fujimori, A., et al., Endocrinology 128(6):3032-3039 (1991)). The explanation for this discrepancy could lie in species differences (in cells and ligand) or in the possible expression by UMR osteosarcoma cells of alternate species of PLC-coupled PTH receptors, the presence of which could not be excluded in rat osteosarcoma cells that also expressed endogenous PTH-1 receptors (Murray, T. M., el al., Calcif. Tiss. Intemat. 49(2):120-123 (1991); Inomata, N., et al., Endocrinology 136(11):4732-4740 (1995)). The failure of N-truncated hPTH-(1-34) analogs studied here to activate PLC via cloned human PTH-1 receptors was not unique to the porcine host cells, however, as these findings were confirmed in both COS-7 cells and in a homologous human cell system as well (data not shown).
- Several major conclusions regarding the interaction of hPTH-(1-34) and the PTH-1 and PTH-2 receptor can be drawn from the results of these experiments. First, it is clear that an intact N-terminus of the hPTH-(1-34) ligand is indispensable for effective activation of PLC via the PTH-1 receptor. Second, although the N-terminus of hPTH is important for activation of both AC and PLC via the PTH-1 receptor, the roles of specific structural features within the N-terminus of the ligand in activating these two effectors are different. Specifically, we found that PLC activation is much more sensitive to the structure of the N-terminus—i.e. both the identity of the N-terminal amino acid and the presence of the N-terminal α-amino group—than is the AC response, which, unlike PLC, can occur normally even in the absence of an amino acid at
position 1. We had previously accomplished such signaling selectivity through mutations in the PTH receptor (by changing the EKKY sequence inintracellular loop 2 to DSEL (Iida-Klein, A., et al., J. Biol. Chem. 272(11):6882-6889 (1997)), but it now is clear that a highly signal-selective ligand, active through the wild type receptor, also can be designed. - Furthermore, because the desamino peptides in these studies did not activate PLC via the PTH-1 receptor but stimulated PLC via the PTH-2 receptor to a
level 50% greater than the maximal responses observed with 1000 nM hPTH(1-34), we conclude that the human PTH-1 and PTH-2 receptors differ in their recognition of key structural features at the N-terminus of the hpTH ligand. Moreover, the greatly reduced efficacy of hPTH(1-34) for AC activation via PTH-2 vs. PTH-1 receptors in cells with comparable receptor expression, together with the enhanced signaling and binding observed with amino-terminally modified hPTH peptides suggests that PTH may not be the natural ligand for the PTH-2 receptor. - Of course, until physiologic levels of PTH-1/PTH-2 receptor expression have been defined in relevant target cells in vivo, estimates of the AC activity of PTH analogs or mimetic compounds obtained using these highly sensitive in vitro systems must be interpreted cautiously. At the same time, such systems appear to offer important advantages for identifying weak human PTH-1/PTH-2 receptor agonists and defining the elemental structural features of ligands involved in binding and multiple parallel signaling by this receptor.
- Careful analysis of the properties of these analogs in vitro and in vivo should help clarify the role of PTH-1/PTH-2 receptor-dependent PLC activation in PTH action(s) and provide further direction for the development of other signal-selective hPTH analogs.
- Further clarification of the significance of these various activation domains for physiological or pharmacological actions of PTH in vivo will require better definition of the roles of key cellular pathways activated by PTH-1/PTH-2 receptor-mediated AC, and PLC signaling. These issues now can be addressed more clearly by comparing biological actions of the N-terminally modified PTH analogs described here with those of N-terminally shortened PTH analogs described by others (Azarani, A., et al.,J. Biol. Chem. 271(25):14931-14936 (1996); Janulis, M., et al., Endocrinology 133:713-719 (1993); Siegfried, G., et al., Endocrinology 136(3):1267-1275 (1995); Rixon, R. H., et al., J. Bone Miner. Res. 9(8):1179-1189 (1994)) that trigger PKC activation but not PLC. For example, we previously found that selective ablation of the PLC response to PTH-(1-34) via mutations within the second intracellular loop of the rat PTHR blocks certain downstream biologic responses, such as sodium-dependent phosphate transport in LLC-PK1 cells (Iida-Klein, A., et al., J. Biol. Chem. 272(11):6882-6889 (1997)) and interleukin-6 production by growth-plate chondrocytes (unpublished data). The availability of novel ligands with receptor specific selective signaling via the wild type PTH-1/PTH-2 receptors now offers a complementary approach to addressing important questions in vitro. Ultimately, careful correlation of in vitro tests with studies of analog activity in vivo will be required to dissect and full define the physiological roles of these separate receptor specific signals.
-
1 10 1 34 PRT Homo sapiens UNSURE (1) Can be desamino Ser, desamino Ala, or desamino Gly 1 Xaa Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 20 25 30 Asn Phe 2 34 PRT Homo sapiens MOD_RES (1) Desamino Gly 2 Gly Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 20 25 30 Asn Phe 3 33 PRT Homo sapiens MOD_RES (1) Desamino Gly 3 Gly Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 20 25 30 Asn 4 27 PRT Homo sapiens MOD_RES (1) Desamino Gly 4 Gly Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys 20 25 5 34 PRT Homo sapiens MOD_RES (1) Desamino Ala 5 Ala Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 20 25 30 Asn Phe 6 33 PRT Homo sapiens MOD_RES (1) Desamino Ala 6 Ala Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 20 25 30 Asn 7 27 PRT Homo sapiens MOD_RES (1) Desamino Ala 7 Ala Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys 20 25 8 34 PRT Homo sapiens MOD_RES (1) Desamino Ser 8 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 20 25 30 Asn Phe 9 33 PRT Homo sapiens MOD_RES (1) Desamino Ser 9 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 20 25 30 Asn 10 27 PRT Homo sapiens MOD_RES (1) Desamino Ser 10 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys 20 25
Claims (29)
1. A biologically active peptide at least 90% identical to a peptide consisting essentially of the formula:
(a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAs nSerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1);
(b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
(c) pharmaceutically acceptable salts thereof; or
(d) N- or C-derivatives thereof;
wherein:
X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2.
2. A biologically active peptide consisting essentially of the formula:
(a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAs nSerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1);
(b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
(c) pharmaceutically acceptable salts thereof; or
(d) N- or C-derivatives thereof;
wherein:
X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31 )NH2 or desamino Ser1 hPTH(1-34)NH2.
3. The peptide of claim 1 which is:
Desamino-AlaValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSer MetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe(SEQ ID NO:5).
4. The peptide of claim 1 which is:
Desamino-GlyValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSer MetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe(SEQ ID NO:2).
5. The peptide of claim 1 wherein the peptide is labeled with a label selected from the group consisting of: radiolabel, flourescent label, bioluminescent label, or chemiluminescent label.
6. The peptide of claim 5 , wherein said radiolabel is 99mTc.
7. A pharmaceutical composition comprising
(a) a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula:
X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe(SEQ ID NO:1);
(b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
(c) pharmaceutically acceptable salts thereof; or
(d) N- or C-derivatives thereof;
wherein:
X01 is desamino Ser, desamino Ala or desamino Gly; and a pharmaceutically acceptable carrier.
8. A pharmaceutical composition comprising
(a) a biologically active peptide consisting essentially of the formula:
X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsnSerMet GluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe(SEQ ID NO:1);
(b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
(c) pharmaceutically acceptable salts thereof; or
(d) N- or C-derivatives thereof;
wherein:
X01 is desamino Ser, desamino Ala or desamino Gly; and a pharmaceutically acceptable carrier.
9. A nucleic acid molecule consisting essentially of a polynucleotide encoding a biologically active peptide which has an amino acid sequence selected from the group consisting of:
(a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsn SerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1);
(b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
wherein:
X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2.
10. A recombinant DNA molecule comprising: (1) an expression control region, said region in operable linkage with (2) a polynucleotide sequence coding for a biologically active peptide, wherein said peptide is selected from the group consisting of:
(a) X01 ValSerGluIleGInLeuMetHisAsnLeuGlyLysHisLeuAsn SerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1);
(b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
wherein:
X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2.
11. A method of preparing a biologically active peptide comprising introducing into a host the recombinant DNA molecule of claim 9 , and causing expression of said molecule.
12. A method for making a recombinant vector comprising inserting a nucleic acid molecule of claim 8 into a vector.
13. The recombinant DNA molecule of claim 9 , wherein said control region includes a bacterial, viral, fungal or mammalian promoter.
14. A host cell containing the recombinant DNA molecule of claim 9 .
15. The cell of claim 13 which is prokaryotic.
16. The cell of claim 14 which is bacterial.
17. The cell of claim 13 which is eukaryotic.
18. The cell of claim 16 which is a yeast cell or a mammalian cell.
19. A method for treating mammalian conditions characterized by decreases in bone mass, which method comprises administering to a subject in need thereof an effective bone mass-increasing amount of a biologically active peptide, wherein said peptide comprises an amino acid sequence at least 90% identical to a member selected from the group consisting essentially of:
(a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsn SerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1);
(b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
(c) pharmaceutically acceptable salts thereof; or
(d) N- or C-derivatives thereof;
wherein:
X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2; and a pharmaceutically acceptable carrier.
20. A method for treating mammalian conditions characterized by decreases in bone mass, which method comprises administering to a subject in need thereof an effective bone mass-increasing amount of a biologically active peptide consisting essentially of the formula:
(a) X01 ValSerGluIleGlnLeuMetHisAsnLeuGlyLysHisLeuAsn SerMetGluArgValGluTrpLeuArgLysLysLeuGlnAspValHisAsnPhe (SEQ ID NO:1);
(b) fragments thereof containing amino acids 1-29, 1-30, 1-31, 1-32, or 1-33;
(c) pharmaceutically acceptable salts thereof; or (d) N- or C-derivatives thereof;
wherein:
X01 is desamino Ser, desamino Ala or desamino Gly, provided that said peptide is not desamino Ser1 hPTH(1-31)NH2 or desamino Ser1 hPTH(1-34)NH2; and a pharmaceutically acceptable carrier.
21. A method for determining rates of bone reformation, bone resorption and/or bone remodeling comprising administering to a patient an effective amount of a peptide of claim 4 and determining the uptake of said peptide into the bone of said patient.
22. The method of claim 19 , wherein said effective bone mass-increasing amount of said peptide is administered by providing to the patient DNA encoding said peptide and expressing said peptide in vivo.
23. A method of claim 19 , wherein the condition to be treated is osteoporosis.
24. A method of claim 19 , wherein said osteoporosis is old age osteoporosis.
25. A method of claim 19 , wherein said osteoporosis is post-menopausal osteoporosis.
26. A method of claim 19 , wherein the effective amount of said peptide for increasing bone mass is from about 0.01 μg/kg/day to about 1.0 μg/kg/day.
27. The method of claim 19 , wherein the method of administration is parenteral.
28. The method of claim 19 , wherein the method of administration is subcutaneous.
29. The method of claim 19 , wherein the method of administration is nasal insufflation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/361,928 US20030144209A1 (en) | 1998-11-25 | 2003-02-11 | Amino -terminal modified parathyroid hormone (PTH) analogs |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11015298P | 1998-11-25 | 1998-11-25 | |
US09/447,800 US6537965B1 (en) | 1998-11-25 | 1999-11-23 | Amino-terminal modified parathyroid hormone (PTH) analogs |
US10/361,928 US20030144209A1 (en) | 1998-11-25 | 2003-02-11 | Amino -terminal modified parathyroid hormone (PTH) analogs |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/447,800 Division US6537965B1 (en) | 1998-11-25 | 1999-11-23 | Amino-terminal modified parathyroid hormone (PTH) analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030144209A1 true US20030144209A1 (en) | 2003-07-31 |
Family
ID=22331485
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/447,800 Expired - Fee Related US6537965B1 (en) | 1998-11-25 | 1999-11-23 | Amino-terminal modified parathyroid hormone (PTH) analogs |
US10/361,928 Abandoned US20030144209A1 (en) | 1998-11-25 | 2003-02-11 | Amino -terminal modified parathyroid hormone (PTH) analogs |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/447,800 Expired - Fee Related US6537965B1 (en) | 1998-11-25 | 1999-11-23 | Amino-terminal modified parathyroid hormone (PTH) analogs |
Country Status (7)
Country | Link |
---|---|
US (2) | US6537965B1 (en) |
EP (1) | EP1175444B1 (en) |
JP (1) | JP2003533167A (en) |
AT (1) | ATE384743T1 (en) |
AU (1) | AU1918300A (en) |
DE (1) | DE69938064T2 (en) |
WO (1) | WO2000031137A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7169567B1 (en) | 1998-12-31 | 2007-01-30 | The General Hospital Corporation | Screening assay utilizing the PTH receptor |
US20070111946A1 (en) * | 1998-10-22 | 2007-05-17 | Gardella Thomas J | Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) |
US20070161569A1 (en) * | 2003-03-19 | 2007-07-12 | Gardella Thomas J | Conformationally constrained parathyroid hormones with alpha-helix stabilizers |
US7479478B2 (en) | 1998-11-25 | 2009-01-20 | The General Hospital Corporation | Human parathyroid hormone modifications, preparation and use |
US7556821B2 (en) | 2004-05-13 | 2009-07-07 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents |
US7572765B2 (en) | 2001-07-23 | 2009-08-11 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (PTH) analogs |
US20100081612A1 (en) * | 2006-08-04 | 2010-04-01 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (pth) |
US20110009328A1 (en) * | 1999-09-29 | 2011-01-13 | The General Hospital Corporation | Polypeptide Derivatives of Parathyroid Hormone (PTH) |
US7910544B2 (en) | 2003-07-17 | 2011-03-22 | The General Hospital Corporation | Conformationally constrained parthyroid hormone (PTH) analogs |
US20110172153A1 (en) * | 2007-08-01 | 2011-07-14 | The General Hospital Corporation | Screening methods using g-protein coupled receptors and related compositions |
US9492508B2 (en) | 2010-05-13 | 2016-11-15 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000032771A1 (en) * | 1998-11-30 | 2000-06-08 | The General Hospital Corporation | Pth1r and pth3r receptors, methods and uses thereof |
ATE403678T1 (en) * | 1998-12-31 | 2008-08-15 | Gen Hospital Corp | PEPTIDES CONSISTING OF TWO FUNCTIONAL PTH DOMAINS LINKED BY A LINKER MOLECULE AND DERIVATIVES THEREOF |
US7057012B1 (en) * | 1998-12-31 | 2006-06-06 | The General Hospital Corporation | PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
WO2002024943A2 (en) * | 2000-09-19 | 2002-03-28 | Curagen Corporation | Method of identifying osteoregenerative agents using differential gene expression |
KR100491737B1 (en) * | 2001-07-20 | 2005-05-27 | 주식회사 한국아이템개발 | Mosquito control apparatus with the effect of air cleaning |
CA2453646C (en) * | 2001-08-17 | 2008-09-30 | Novartis Ag | 5-cnac as oral delivery agent for parathyroid hormone fragments |
US7906480B2 (en) | 2002-05-23 | 2011-03-15 | Michael Holick | Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy |
WO2003105772A2 (en) * | 2002-06-13 | 2003-12-24 | Beth Israel Deaconess Medical Center, Inc. | Analogs of parathyroid hormone and pth-related protein as bone anabolic agents |
AU2002951372A0 (en) * | 2002-09-13 | 2002-09-26 | St Vincent's Institute Of Medical Research | Parathyroid hormone-like polypeptides |
US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
AU2004257362A1 (en) * | 2003-07-15 | 2005-01-27 | National Research Council Of Canada | Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells |
EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
US20090023655A1 (en) * | 2007-04-02 | 2009-01-22 | Louis Luttrell | Biased Ligands for Receptors Such as the PTH Receptor |
CN102448482A (en) | 2009-03-27 | 2012-05-09 | 范安德尔研究所 | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use |
EP3765061A4 (en) | 2018-03-16 | 2022-01-26 | The General Hospital Corporation | Parathyroid hormone polypeptide conjugates and methods of their use |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4423037A (en) * | 1982-05-13 | 1983-12-27 | The General Hospital Corporation | Inhibitors of peptide hormone action |
US4698328A (en) * | 1985-04-04 | 1987-10-06 | The General Hospital Corporation | Method of increasing bone mass |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5605815A (en) * | 1988-03-14 | 1997-02-25 | Yale University | Nucleic acids encoding and expression of parathyroid hormone-like peptide |
US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
US6051686A (en) * | 1992-07-14 | 2000-04-18 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
US6066618A (en) * | 1987-10-20 | 2000-05-23 | Holick; Michael F. | Regulation of cell proliferation and differentiation using peptides |
US6417333B1 (en) * | 1998-11-25 | 2002-07-09 | The General Hospital Corporation | Modified human parathyroid hormone |
US6495662B1 (en) * | 1998-10-22 | 2002-12-17 | The General Hospital Corporation | Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) |
US6541220B1 (en) * | 1998-11-30 | 2003-04-01 | The General Hospital Corporation | Nucleic acid encoding PTH1R receptor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5896052A (en) * | 1981-11-30 | 1983-06-07 | Toyo Jozo Co Ltd | Preparation of highly active h-pth (1-34) amide |
JPS59204159A (en) * | 1983-04-28 | 1984-11-19 | Toyo Jozo Co Ltd | (met(o)8,18)hpth-(1-34)peptide |
-
1999
- 1999-11-23 AT AT99962819T patent/ATE384743T1/en not_active IP Right Cessation
- 1999-11-23 EP EP99962819A patent/EP1175444B1/en not_active Expired - Lifetime
- 1999-11-23 US US09/447,800 patent/US6537965B1/en not_active Expired - Fee Related
- 1999-11-23 DE DE69938064T patent/DE69938064T2/en not_active Expired - Lifetime
- 1999-11-23 AU AU19183/00A patent/AU1918300A/en not_active Abandoned
- 1999-11-23 JP JP2000583963A patent/JP2003533167A/en active Pending
- 1999-11-23 WO PCT/US1999/027656 patent/WO2000031137A1/en active IP Right Grant
-
2003
- 2003-02-11 US US10/361,928 patent/US20030144209A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4423037A (en) * | 1982-05-13 | 1983-12-27 | The General Hospital Corporation | Inhibitors of peptide hormone action |
US4698328A (en) * | 1985-04-04 | 1987-10-06 | The General Hospital Corporation | Method of increasing bone mass |
US6066618A (en) * | 1987-10-20 | 2000-05-23 | Holick; Michael F. | Regulation of cell proliferation and differentiation using peptides |
US5605815A (en) * | 1988-03-14 | 1997-02-25 | Yale University | Nucleic acids encoding and expression of parathyroid hormone-like peptide |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
US6051686A (en) * | 1992-07-14 | 2000-04-18 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
US6495662B1 (en) * | 1998-10-22 | 2002-12-17 | The General Hospital Corporation | Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) |
US6417333B1 (en) * | 1998-11-25 | 2002-07-09 | The General Hospital Corporation | Modified human parathyroid hormone |
US6541220B1 (en) * | 1998-11-30 | 2003-04-01 | The General Hospital Corporation | Nucleic acid encoding PTH1R receptor |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7985835B2 (en) | 1998-10-22 | 2011-07-26 | The General Hospital Corporation | Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) |
US20070111946A1 (en) * | 1998-10-22 | 2007-05-17 | Gardella Thomas J | Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) |
US7479478B2 (en) | 1998-11-25 | 2009-01-20 | The General Hospital Corporation | Human parathyroid hormone modifications, preparation and use |
US20070117969A1 (en) * | 1998-12-31 | 2007-05-24 | Gardella Thomas J | PTH receptor and screening assay utilizing the same |
US7169567B1 (en) | 1998-12-31 | 2007-01-30 | The General Hospital Corporation | Screening assay utilizing the PTH receptor |
US20110009328A1 (en) * | 1999-09-29 | 2011-01-13 | The General Hospital Corporation | Polypeptide Derivatives of Parathyroid Hormone (PTH) |
US8568736B2 (en) | 1999-09-29 | 2013-10-29 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (PTH) |
US7572765B2 (en) | 2001-07-23 | 2009-08-11 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (PTH) analogs |
US8603977B2 (en) | 2001-07-23 | 2013-12-10 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (PTH) analogs |
US20070161569A1 (en) * | 2003-03-19 | 2007-07-12 | Gardella Thomas J | Conformationally constrained parathyroid hormones with alpha-helix stabilizers |
US7795220B2 (en) | 2003-03-19 | 2010-09-14 | The General Hospital Corporation | Conformationally constrained parathyroid hormones with alpha-helix stabilizers |
US7910544B2 (en) | 2003-07-17 | 2011-03-22 | The General Hospital Corporation | Conformationally constrained parthyroid hormone (PTH) analogs |
US7556821B2 (en) | 2004-05-13 | 2009-07-07 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents |
US8361022B2 (en) | 2004-05-13 | 2013-01-29 | Alza Corporation | Apparatus for transdermal delivery of parathyroid hormone agents |
US8143374B2 (en) | 2006-08-04 | 2012-03-27 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (PTH) |
US20100081612A1 (en) * | 2006-08-04 | 2010-04-01 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (pth) |
US8568737B2 (en) | 2007-08-01 | 2013-10-29 | The General Hospital Corporation | Screening methods using G-protein coupled receptors and related compositions |
US20110172153A1 (en) * | 2007-08-01 | 2011-07-14 | The General Hospital Corporation | Screening methods using g-protein coupled receptors and related compositions |
US9057727B2 (en) | 2007-08-01 | 2015-06-16 | The General Hospital Corporation | Screening methods using G-protein coupled receptors and related compositions |
US9492508B2 (en) | 2010-05-13 | 2016-11-15 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2000031137A1 (en) | 2000-06-02 |
AU1918300A (en) | 2000-06-13 |
EP1175444A1 (en) | 2002-01-30 |
JP2003533167A (en) | 2003-11-11 |
EP1175444B1 (en) | 2008-01-23 |
DE69938064D1 (en) | 2008-03-13 |
DE69938064T2 (en) | 2009-01-15 |
ATE384743T1 (en) | 2008-02-15 |
US6537965B1 (en) | 2003-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6537965B1 (en) | Amino-terminal modified parathyroid hormone (PTH) analogs | |
US6417333B1 (en) | Modified human parathyroid hormone | |
US7985835B2 (en) | Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) | |
US8568736B2 (en) | Polypeptide derivatives of parathyroid hormone (PTH) | |
US7244834B2 (en) | Nucleic acids encoding PTH functional domain conjugate peptides | |
US20080058505A1 (en) | PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules | |
US7022815B1 (en) | Polypeptide derivatives of parathyroid hormone (PTH) | |
EP1222208B1 (en) | Polypeptide derivatives of parathyroid hormone (pth) | |
US8143374B2 (en) | Polypeptide derivatives of parathyroid hormone (PTH) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRINGHURST, F. RICHARD;TAKASU, HISASHI;GARDELLA, THOMAS J.;REEL/FRAME:017683/0219;SIGNING DATES FROM 20000210 TO 20000214 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |